ArticlePDF Available

SARS-CoV-2 and the Vaccination Hype

Authors:
  • Edge-Institute (edge-institute.org)

Abstract and Figures

The engineered spike protein of SARS-COV-2, and the corresponding infectious disease COVID-19 attributed to it, hold in their grip a large portion of humanity. The global race for a counter strategy quickly turned into a search for a vaccine as the preferred means to contain the virus. An unusually rapid development of different and completely new classes of experimental therapies that would widely be referred to as “vaccines” raised questions about safety, especially with regard to emergency use approval (EUA) being granted with unprecedented urgency and hardly any critical scrutiny. At present, independent researchers, even some former proponents and insiders, of the currently ongoing global experiment represented as a “vaccination” campaign point primarily to the lack of public safety studies based on empirical datasets that should be obtainable for the tens of millions, even hundreds of millions, of doses of mRNA and DNA vector therapeutics being distributed as “vaccines”. Studies regarding efficacy and “side effects” (sometimes fatalities or permanent iatrogenic injuries) of these experimental therapies have been by-passed in favor of short-term field data from real patients which inevitably raises scientific and ethical questions particularly in view of the fact that the persons and entities responsible for public safety hold deep financial and other vested interests in speeding along the distribution of the experimental pharmaceutical products. The lack of an open discussion about the experimental therapies for COVID-19 now being applied across all age groups, even children hardly impacted by COVID-19, is worrying. The core principle of open debate without pre-conceptions or vested interests in outcomes has been and continues to be utterly ignored. We hope to engage scientific discussion that will help decision-makers, the general public, and the media alike to consider the subject-matter of what is at stake in a context of reason rather than panic.
Content may be subject to copyright.
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 173
SARS-CoV-2 and the Vaccination Hype
Piero Sangaletti1, Jane Doe2, Antonietta Gatti3,, Clemens Arvay4, Livio Giuliani5, and Herbert Lettner6
1Edge-Institute Austria at ER-System Mechatronics, Golling, Austria: abocs@protonmail.ch
2ABoCS (Advisory Board of Concerned Scientists), Tampa, Florida USA
3Cofounder and Principal Investigator of Nanodiagnostics, SRL (Società a Responsabilità Limitata), Italy
4Independent scientist and textbook author in Health Ecology, Vienna and Graz, Austria
5International Commission for Electromagnetic Safety (ICEMS), Rome, Italy
6Department of Chemistry and Physics of Materials, University of Salzburg, Salzburg, Austria
ABSTRACT
The engineered spike protein of SARS-COV-2, and the corresponding infectious disease COVID-19 attributed to it,
hold in their grip a large portion of humanity. The global race for a counter strategy quickly turned into a search for a
vaccine as the preferred means to contain the virus. An unusually rapid development of different and completely new
classes of experimental therapies that would widely be referred to as “vaccines raised questions about safety, especially
with regard to emergency use approval (EUA) being granted with unprecedented urgency and hardly any critical scrutiny.
At present, independent researchers, even some former proponents and insiders, of the currently ongoing global
experiment represented as a “vaccination campaign point primarily to the lack of public safety studies based on
empirical datasets that should be obtainable for the tens of millions, even hundreds of millions, of doses of mRNA and
DNA vector therapeutics being distributed as “vaccines”. Studies regarding efficacy and side effects” (sometimes
fatalities or permanent iatrogenic injuries) of these experimental therapies have been by-passed in favor of short-term
field data from real patients which inevitably raises scientific and ethical questions particularly in view of the fact that the
persons and entities responsible for public safety hold deep financial and other vested interests in speeding along the
distribution of the experimental pharmaceutical products. The lack of an open discussion about the experimental
therapies for COVID-19 now being applied across all age groups, even children hardly impacted by COVID-19, is
worrying. The core principle of open debate without pre-conceptions or vested interests in outcomes has been and
continues to be utterly ignored. We hope to engage scientific discussion with the hope of helping decision-makers, the
general public, and the media alike to consider the subject-matter of what is at stake in a context of reason rather than
panic.
Keywords: COVID-19 vaccination, quasi-species consortia, mRNA-/vector-vaccine, SARS-CoV-2
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 174
1. Introduction
Within a short time after the emergence over a year ago in China of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), and its subsequent spread as COVID-19, the alleged global pandemic that
followed supposedly caused more than 304 million infections with 5.5 million deaths also attributed to the
virus (Gardner et al., 2021 as of December 2021). The disease statistics revised hour by hour were all the
while being confirmed by health officials using more than 30 cycles of polymerase chain reaction (PCR)
testing in a manner guaranteed to produce a huge number of false positive COVID-19 cases as shown by
Kucirka et al., (2020) and Watson et al., (2020). Nevertheless, the US Centers for Disease Control and
Prevention (CDC) has continued up to the present time to use up to 45 amplification cycles of PCR to
diagnose hundreds of thousands of cases of “COVID infections” in spite of the fact that the inventor of
the PCR procedure himself, Kary Mullis (1986), insisted that PCR was and is inappropriate for diagnosing
any disease whatsoever (see video clip BL, 2020). An observation in line with Chang et al., (2020) who likewise
pointed out that there is a lack of a clear-cut “gold-standard” for COVID-19 testing. A more reliable
diagnostic method for direct demonstration of coronavirus antigens in nasopharyngeal aspirates or swabs
makes use of monoclonal antibodies (White & Fenner, 1994). Given the drawback that coronaviruses are
difficult to grow in vitro, isolation from diploid fibroblast cell lines also provides reliable results (Burrell et
al., 2016). Moreover, deaths were often attributed to COVID-19 as decreed after the fact by some health
official without the deceased ever having manifested symptoms or having been certified as infected with
SARS-CoV-2. For documentation, (Loffredo, 2021 quoting John O'Looney; Kennedy, 2021, p. 772). To
our knowledge, exceedingly few of the deaths attributed to COVID-19 were ever verified by the gold-
standard of a careful autopsy, and none of the deaths dealt with personally by John O’Looney were
autopsied. None of the persons he dealt with ever showed symptoms of COVID-19 nor were they ever
diagnosed as having contracted it while they were still living according to their family members.
Nonetheless, COVID-19 was registered as the cause of death by health officials.
1.1 Media Attention
In the hype of media attention that followed the first reported infections and deaths, and particularly after
the lockdown impacting the developed nations world-wide in March 2020, it was hardly clear whether any
particular death attributed to COVID-19 was of an individual who died after being designated as a “case”
infected by SARS-CoV-2, or whether the deceased person was actually killed by the virus (Madl et al., 2021).
In the meantime, a frantic search for a quick fix was launched at the expense of taxpayers, which search a
few months later resulted in several candidate “vaccines” being released by emergency use authorization
(EUA).
1
To understand the “patho-physiology” of this novel disease, dubbed COVID-19, in the days and
weeks following the outbreak, it became known that the new virus (in several variants) interferes in manifold
ways with the host genome. For the details, readers are referred to Fleming (2021). He documents and cites
(1) the long public record of research findings reported in prestigious scientific journals, (2) the stream of
lucrative patents for virus components and the like, and (3) the series of government grants for millions of
dollars in a little more than 141 pages showing how SARS-CoV-2 was manipulated over several years, even
decades, leading up to the “pandemic” that would become known as COVID-19. The genomic interference
attributed to the virus, or more correctly according to Fleming, caused by its genetically engineered spike
protein (see our Figure 1) triggers what Blaylock (2021) has termed a cytokine storm, and which according
to Dotan et al. (2021) is also associated with a host of distinct antibodies as well as autoimmune diseases.
Due to its molecular mimicry of human sequences, the spike protein of SARS-CoV-2 readily binds with the
1
On Dec. 9th, EUA-status for Comirnaty has been amended by the US-FDA; https://www.fda.gov/news-events/press-
announcements/coronavirus-covid-19-update-fda-expands-eligibility-pfizer-biontech-covid-19-booster-dose-16-and-17.
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 175
membrane based ACE2 (angiotensin converting enzyme 2) receptors (Guzik et al., 2020; South et al., 2020)
present in various cell types found in the human lungs, heart, blood vessels, kidneys, liver, testes, and
gastrointestinal tract (Figure 1).
Figure 1.Visualization of SARS-
CoV-2 (center) with its
ultrastructural morphology.
Grouped around the virus
appear autoantibodies (left) and
autoimmune diseases (right),
both linked to the SARS-CoV-2-
infection (modified after Dotan
et al., 2021). However, the
autoimmune diseases may also
be relevant to the associated
“side effects” of the
experimental therapies now
being represented to the public
as “vaccines”. Note that the
specific named diseases and
corresponding auto-antibodies
are not actually associated with
the particular locations on the
SARS-CoV-2 virus suggested in
this artwork, but are nonetheless
well-attested in relevant research.
As highlighted below, the widespread presence of the ACE2 receptor within the human body makes those
cells likely targets of opportunity for potential adverse effects following vaccination. In the majority of cases,
a COVID-19 infection passes rather quickly with hardly any noteworthy symptoms. However, in a small
percentage of cases, the infected persons report body aches with fever and other flu-like symptoms. But
severe cases are relatively rare and deaths unambiguously attributable to SARS-CoV-2, account for only
about 6% of the total number of COVID-19 deaths reported by the CDC numbers, as already noted,
greatly inflated by a huge percentage of the “cases” falsely diagnosed as positive for COVID infection by
the inappropriate use of PCR tests with an absurdly high number of cycles (see the Fleming, 2021 reference
cited above). Even so, 94% of the observed fatalities originally attributed to COVID infection, as admitted
by the CDC (2020), involved one or more co-morbid disease conditions. Those conditions cannot be
excluded as contributing to or possibly causing any one or many of the deaths in question that were
attributed to COVID-19. Autopsies performed on hospitalized COVID-19 patients that did not recover
revealed conditions such as respiratory failure associated with diffuse alveolar damage, and/or multiple-
organ failure, cardiac decompensation, complication due to malignant tumors, septic shock, and various
other chronic disease conditions and serious disorders. The commonly associated risk factors for severe life-
threatening SARS-CoV-2 infections included a litany of life-style-issues such as obesity and hypertension, as
well as serious disease conditions such as tumors and diabetes mellitus, or the patients who died were
advanced in years with overall poor health. In many instances fatalities involved people who were, already,
nearing the end of their lives before the onset of the COVID-19 “pandemic” attributed to SARS-CoV-2.
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 176
1.2 A Common Dysfunction in Recipients of the Experimental Injections
One common injury attributed to the virus in its various forms was vascular dysfunction with altered
endothelial metabolism not only in the lungs but in almost any organ that was closely examined in the
severely ill or deceased persons (Haberecker et al., 2021). Given that patients with pre-existing endothelial
dysfunction already have a suppressed capacity to restore injured vasculature and are already inhibited by
micro-thrombosis, they are particularly vulnerable to the impact of any variant of SARS-CoV-2.
With all this in mind, it seems stranger than ever that the current spectrum of mRNA and genome vectoring
“vaccines” have been granted emergency release at all. Bearing in mind that the therapies in question (see
further explanation in reference to our Figure 2 below on page 180) are radically different from traditional
vaccines insofar as these new experimental therapies aim to control certain genetic processes formerly, but
now no longer, out of the reach of medical interventions. For that reason, in this paper we refer to any of
the experimental COVID-19 injections as a “disease component replicating therapy”, or a “DiCoReTh-
injection” for short. As will be shown later, the associated side effects unintended iatrogenic
consequences consisting of injuries of various sorts, some of which are already occurring and others that are
known to be possible, even likely, downstream of these novel classes of experimental genetic therapies
logically must interact negatively with the comorbidities that evidently have actually led to some severe or
even fatal infections by SARS-CoV-2. One of the prominent and obvious dangers, known to those
examining the research on DiCoReTh-injections, is that the genome interference brought into hundreds of
millions of people by these experimental injections are virtually certain to aggravate any existing distressed
endothelial metabolism causing, among other undesirable effects, micro-thrombosis (McCullough et al.,
2021). Personal accounts of adverse effects in an oral history format can be accessed via the testimonials
project (Livny, 2021).
2.0 The Normal Human Virus Sphere Disrupted?
Viruses are believed to be essential and dominant players in microbial ecology (Moelling, 2017), and yet
fairly little is known about the patho-physiology of those that can cause disease, their relevant threshold
levels, their possible sources (means of transmission), and modes of transformation. The family of single
stranded RNA (ssRNA) viruses to which SARS-CoV-2 belongs has peculiar properties as it has
enormous genomic flexibility, on the one hand and species-specific persistence, on the other. These viruses,
as a result, have genetic stability in their own right and at the same time can co-evolve along with changes
occurring in their host cells including the manufacture of antibodies against the viruses by the host. Under
laboratory conditions, these viruses generate different gene populations in rather short periods of time.
However, under natural conditions, without the kinds of artificial disturbances as ordinary vaccine injections
produce, viruses themselves tend to maintain significant homogeneity resulting in molecular clocks that run
much more slowly than those that seem to be in play with the so-called acute viruses (Villarreal, 2005)
which change more quickly. In the case of SARS-CoV-2, Fleming (2021) documents published research
showing how this particular virus was modified by gain-of-function research and was pre-designed for very
rapid changes enabling its downstream variants to adapt at Warp Speed to changing conditions in the host
population. Given that hundreds of millions of humans have already been impacted by injections containing
the genetic vectoring to generate countless copies of the mutating spike protein itself, SARS-CoV-2 is, it
seems, assured of rapid and constant mutation. All this is confirmed by genetic analyses performed six
months after the infected persons studied were diagnosed. Results showed dramatic genetic modifications in
the novel “mutated” genome compared to its original sequence. The most prominent alterations were in the
spike-protein itself at D614G (Zhang et al, 2020a), E484K (Wise, 2021), B.1.1.7 (Rambaut et al., 2020),
B.1.351 (Lessells, 2021). Some of the variants found had already been observed, but new variants were
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 177
appearing continuously all the while that such analyses of the SARS-CoV-2 variants were being done (CDC,
2021a; ECDC, 2021, Tablizo et al., 2021).
2.1 Quasi-Species Consortia (qS-c)
While mutations are one concern, quasi-Species consortia (qS-c) quite analogous to quorum sensing in
bacteria (Miller and Bassler 2001, Waters and Bassler 2005) represent another means by which the virus
can adapt and increase its own infectivity in hosts. Behavioral motifs of cooperative RNA-agents are the
drivers behind the basic viral skills required to invade and infect hosts and which are responsible for the
synthesis of de novo nucleotide sequences in the host’s genomic economy. Changes in the host’s genetic
material can come about by the virus effecting an insertion, substitution, or deletion in native host
sequences (Villarreal and Witzany, 2013; Villarreal, 2015). This means that for every variant (1) a given
nucleic acid sequence does not maintain a unique position, but rather depends on its context of use; which
in turn implies that (2) the nucleotide sequences follow real-life conditions that aren’t randomly arranged.
The far-reaching effects of such variations as observed under laboratory conditions are much broader: qS-c
(1) concur in related populations and exclude relatives; (2) possess minority populations that are essential for
overall fitness; (3) exhibit heterogeneity which is important for fitness but is not observed in the consensus
type; (4) are able to repress their own replication through lethal defects; and (5) are composed of members
that interfere with the replication of the collective. Hence, qS-c populations are highly diverse, and it is
assumed that no two genomes therein are identical even if a cloned genetically homogeneous template is
used to trigger a cycle of infection (Villarreal and Witzany, 2013; 2021), it will not remain identical to its own
starting sequence. This fact is relevant to the ongoing “pandemic” and the EUA DiCoReTh-injections
that are claimed to have the power to stop it. The fact that a non-negligible number of people continue to
test positive for COVID-19 long after the infection, and all the symptoms formerly prominent, are gone,
suggests that the specific RNAs of SARS-CoV-2 can be and are being reverse-transcribed into human cells
(Zhang et al 2020b; Desfarges & Ciuffi, 2012; Villarreal & Witzany, 2021). In patients recovered from Long-
COVID-19 (Raveendran et al., 2021), an unusually elevated concentration of G-protein coupled receptors
tied to functional autoantibodies (GPCR-fAABs) have been detected in their serum. Associated symptoms
included alopecia, fatigue, tachycardia, bradycardia, and myocarditis among others (Wallukat et al 2021). So
far, only a few cases are available showing host-virus chimeric reads in RNA-sequencing data from SARS-
CoV-2 infected cells and samples from COVID-19 patients that would suggest viral integration into the
human genome (Yan et al., 2021). Hence, only follow-up studies of Long-COVID cases will show whether
this can be determined for sure (Lopez-Leon et al., 2021).
2.2 Cells and Tissues Known to Be Impacted
There is a third concern for human endogenous retroviruses (HERV) fulfilling crucial life functions
(Villarreal, 2005) in particular non-coding retroviral RNA sequences within the human genome are
responsible for editing tasks. Phylo-ontogenetically speaking, this feature accounts for crucial competencies
such as the production of replicase, polymerase, integrase, DNA-repairs, restriction/modifications of gene
expression, methylation, the eukaryotic nucleus, the division of transcription and translation, the creation of
nuclear pores, tubulin-based chromosome duplication, empowering of the innate immune system, the
adaptive immune system, health in cartilage, bones, skin, mucus, milk, the placenta, viviparity just to name a
few (Witzany, 2006). Why does this matter? Because at least two of the ongoing DiCoReTh-injection
platforms use RNA and DNA technology (Lurie et al., 2020) and according to Lyons-Weiler (2020) reveal
immunogenic epitope similarities of SARS-CoV-2 with homologues to human proteins. Adiguzel (2021)
drew attention to residual alignments to SARS-CoV-2 peptide with almost a dozen known human proteins.
Moreover, over-expression of the spike protein significantly suppresses both homologous recombination
and non-homologous end joining (Jiang & Mei, 2021), processes that are essential for DNA repair in cells.
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 178
Autoimmune reactivity in response to viral antigens following infection or vaccination can easily be derived
from cross-reaction with human tissue antigens that share sequence homology with the virus; this includes
cells in the heart muscle, skeletal muscles, thyroid gland, kidneys, brain, pituitary gland, testes, lung, blood,
gastrointestinal tract, eye, liver, bone marrow, adipose tissue, skin, and many ubiquitous proteins (Vojdani et
al., 2021). The major autoimmune findings related to SARS-CoV-2 regard anti-phospholipid, anti-nuclear, p-
& c-anti-neutrophil cytoplasmics, anti-cyclic citrullinated peptides, and anti-gangliosides GD1b antibodies
(Salle, 2021). Given that the viral spike protein is a potential epitopic target for biomimicry-induced
autoimmunological processes it will be extremely important to see if GPCR-fAABs will also become
detectable after vaccination against the virus (Wallukat et al 2021).
3.0 The Novel Class of DiCoReTh-Injections
About a third of the potentially targeted human proteins (putative autoantigens) are key players in the
adaptive immune system. Thus, a gene-based-therapy by any DiCoReTh-injection could generate a series
of “side effects”. Specifically, binding antibodies, that do not neutralize themselves, but only bind to the
surface of the virus-infected cell, may render the viral particle invisible to the immune system. Practically
speaking, such a stealth mode can amplify viral replication, and, in that way can make subsequent
infections more severe an effect known as antibody-dependent enhancement (ADE). Such an effect
depends on how antibodies target different epitopes of the spike protein (Iwasaki & Yang, 2020). Indeed,
ADE was observed almost two decades ago when SARS and MERS first became known (Lee at al., 2020).
It has been documented to occur through two distinct processes in viral infections: for one, enhanced
antibody-mediated uptake into Fc gamma receptor IIa (FcγRIIa) expressing phagocytic cells can lead to
increased viral infection and replication, or, for the other, by excessive antibody Fc-mediated effector
functions or immune complex formation causing enhanced inflammation and thus immunopathology. Both
ADE pathways can occur when non-neutralizing antibodies, or antibodies at sub-neutralizing levels, bind to
viral antigens without blocking or clearing them to prevent any infection (again, see Lee et al., 2020). ADE is
marked symptomatically by the fact a secondary infection is more severe than the primary infection was
(Grenfell et al., 2004).
As a result, ADE affects safety and efficacy of passive and active immunization schedules (Negro, 2020; Xu
et al., 2021). To reduce the risk of such pathogenic priming, all the parts of the epitopes that are
homologous to human proteins ought to be excluded from any candidate DiCoReTh-injection/genetic
therapies (Cappello et al., 2020). Yet, all DiCoReTh-injections target human protein biosynthesis aiming to
manipulate the RNA translation at the ribosome level in order to induce the production of viral proteins as
antigens, usually spike proteins see also the “vaccine” package leaflets (WHO, 2021; EMA, 2021c,d,e,f).
In addition, the allergenic potential of novel adjuvants such as PEG and polysorbate (Garçon et al., 2012;
Wang et al., 2010), also commonly referred to as excipients and which are present in DNA vector therapies
as well as the mRNA DiCoReTh-injections, must be taken into account. Furthermore, the lipid
nanoparticles encapsulating mRNA components of the mRNA-based DiCoReTh-injections may contain
conjugated adjuvants or may themselves act as “adjuvants” (Chung et al., 2020; Kim et al., 2021; Zhang &
Xia, 2021) all of this making iatrogenic injuries even more probable (Coors et al., 2005; Jackson et al.,
2020; Cabanillas et al., 2020; deVrieze, 2021; Kim et al., 2021; Kostoff et al., 2021). For example, Pujol et al.
(2021) report on three cases of thyroiditis which they diagnose as adjuvant induced acute inflammation
(ASIA) “induced by the mRNA-based SARS-CoV-2 vaccination”. With such warning signals in mind,
DiCoReTh-injections with the EUA designation already granted: i) should not be deemed to have
established a standard of prevention in the settings where they are being introduced (Singh & Upshur,
2020); ii) should require that unresolved safety concerns be properly addressed (Bruno er al., 2021); and iii)
should be used only after conventional therapies have been exhausted (Shi, 2020; Inserra et al., 2021; de
Melo et al., 2021; McCullough et al., 2021; SWPRS, 2021; Nair et al., 2021). In other words, EUA
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 179
experimental therapies such as the genetic DiCoReTh-injections addressing the COVID-19 “pandemic”
should only be used if less invasive conventional therapies have failed (Janiaud, et al, 2021; McCullough et
al., 2021).
2
3.1 A “Trojan Horse” Effect?
Although the evidence is limited, it appears already that the implementation of genetically modified so-
called “vaccines” actually experimental genetic therapies may interfere with the target cells genome
leading to the activation of oncogenes and/or deactivation of anticarcinogenic gene sequences, thus
increasing cancer risks (Ura et al., 2014; Hasson et al., 2015; Aubrit et al, 2015). However, the few studies
available underline the likelihood of the actual integration of the components of these “vaccines” into the
human genome. Such incorporations into a person’s DNA may occur owing to i) viral mRNA and
adenovirus vector DNA (Doerfler, 2021) with epigenetic consequences yet to be determined; ii) SARS-
COV-2 infections whereby copies of viral subgenomic RNAs may integrate into the DNA of the host cell
via reverse transcription the latter being a suspected cause for symptomatic infections long after the
symptoms and evidence of initial infection have cleared (Zhang et al., 2021).
Such an undesirable Trojan Horse effect is likely if the transferred nucleic acids designed to mimic human
genes are actually integrated into human protein biosynthesis (Chiu et al., 2021; Mansuriya & Altintas, 2021;
Xu et al., 2021). Independent researchers examining genetic DiCoReTh-injections, therefore, point out that
any short-cuts to clinical evaluations for the development of experimental injections against COVID-19,
especially when based on the transduction of nucleic acids (themselves capable of unknown adjuvant-type
“side-effects” such as thyroiditis; Pujol et al., 2021), would be a violation of the precautionary principle
(Jiang, 2020; Arvay, 2020; Rosenthal and Cummings, 2021). In the long run, and as seen with SARS almost a
decade ago, it is shocking, even potentially horrifying, to consider how the novel DiCoReTh-injections
introduced into hundreds of millions of people may, over the coming weeks, months, and years, alter
specific functions of the human body, especially by damaging the immune system. Autoimmune diseases
such as Guillain-Barré Syndrome (Shao et al., 2021), autoimmune induced hepatitis (Avci &Abasiyanik,
2021), and acute autoimmune transverse myelitis (Hirosae et al., 2021) along with a wider spectrum of
autoimmune phenomena (Chen et al., 2021) have been attributed to the novel DiCoReTh-injections.
Evidence is even mounting that repeated vaccinations with the same antigen at short intervals (booster
shots) destabilise the immune system so that autoimmune processes are triggered (Tsumiyama et al., 2009)
and in some cases are lethal (Shimoyama et al., 2021).
None of the foregoing outcomes should be surprising given the tumorigenicity of cell substrates used in the
production of the constituents of the DiCoReTh-injections which may include the use of tumor allografts,
transfer of known or unknown viruses, and the intentional incorporation of oncogenic agents or cell
components that may produce de novo or re-ignite existing cancerous cells (Aubrit 2015; Arvay, 2020; Sumi et
al., 2021; Goldman et al., 2021; VAERS, 2021
3
). Grave adverse potentials arise as the source material for the
manufacture of DiCoReTh-injections rely on animal cell lines in-vitro. Combined with the fact that modified
designer cell lines derived from duck, monkey, and dog tissues, as well as human embryonic kidney
2
It was after a year of crisis management with emergency-approved vaccines although the EU would finally come back to
conventional therapies of which five seemed to get clearance (EC, 2021a).
3
Examples of a 30 min search for tumor triggers and tumor progression after DeCoReTh injections on the VAERS database
yield numerous cases; the corresponding VAERS-IDs are: 1027247, 1039221, 1046027, 1066305, 1073882, 1096952, 1124577,
1103186, 1470499, 1471305, 1478347, 1485987, 1486583, 1538755, 1558249, 1587116, 1582941, 1623680, 1641095, 1646951,
1647170, 1647308, 1651636, 1664657, 1664813, 1665051, 1666115, 1669875, 1684985, 1685076, 1697379, 1714282, 1714343,
1997540, and so forth.
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 180
cells, known under brand names like EB66®, AGE1.CR®, PER.C6®, HEK 293, etc. are being used for
the production of novel influenza vaccines along with the new DiCoReTh-injections not only raises ethical
questions, but could open a Pandora’s box inside human cells (Hsee and Ruan, 2016).
3.2 One or More Self-Replicating Disease Components?
The currently most popular DiCoReTh-injection platforms opted to include RNA-, DNA-, vector-,
inactivated, live attenuated-, and protein-subunit-“vaccines” (Ng et al., 2020). So far, RNA and vector
“vaccines” have been given priority for widespread use in the general public see Figure 2; for regular
updates on their distribution see Mathieau et al. (2021). Yet these experimental “DiCoReTh-injections are
not without known risks. As nanotechnology drugs, which in their essence are gene-therapies, they aim to
cause host cells to produce the exogenous active viral component a disease agent or component of the
suspected cause of disease. As mRNA-based DiCoReTh-injections contain the spike glycoprotein (S) of
SARS-CoV-2 encapsulated in lipid nanoparticles (LNPs) (EMA, 2021c), the encapsulation itself being an
adjuvant (Chung et al., 2020; Kim et al., 2021; Zhang & Xia, 2021) represents an intentional Trojan horse
that can by-pass the sensors on the cell membrane and can enter the sacrosanct region of the nucleus and
nucleolus undetected. There it can set up a “core facility” as a manufacturer of whatever variants of the
disease component it may already be programmed to construct, or that may arise based on modifications of
the genome of the disease component that may occur after the DiCoReTh-injection has done its preliminary
work. The design is such that the liposomes won’t activate an immediate defensive response. While pure
RNA sections are instantaneously recognized and upon entrance into the cell become neutralized, an LNP is
easily phagocytized and penetrates the cytoplasm where the external lipid membrane is degraded releasing
the glycoprotein load.
The use of vector DiCoReTh-injections involves recombinant adenovirus type-5 (Ad5) vectors that have
already been found to be problematic in studies associated with HIV. Participants involved in such studies,
after being artificially infected with the adenovirus, tested positive and as such were at elevated risk of HIV-
1 infection (Buchbinder et al., 2020).
Figure 2. Traditional intramuscular injection of viral proteins (left); RNA injection designed to enable the cell to produce the
active component of the “vaccine” itself (center); and vector introduced via gene shuttle also aiming to produce the active
“vaccine” component (right). The dashed lines represent the hypothetical case where the injected RNA is reverse transcribed
or the DNA becomes persistently integrated into the host cell genome. Collectively, the models in the middle and at the right
of the figure represent the intended working of what we are calling “DiCoReTh-injections”.
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 181
3.3 Emergency Use Authorization for Half-Baked Ideas?
Up until the COVID-19 crisis, no mRNA drug or DiCoReTh-injection had been licensed for use in
humans. There was a feasibility study with an RNA-DiCoReTh-injection several years ago (Bahl et al., 2017),
but given that the technology is still in its infancy, it is not surprising that it is exceedingly difficult to get
RNA into cells without triggering serious “side effects” (NatBiotech, 2016). On theoretical grounds, based
on many different disease conditions, Oller and Shaw (2019) showed how any penetration into the nucleus,
particularly the nucleolus where the main cache of DNA is stored and normally well-protected against
toxicants and other invasive factors, appears to be essential to the initiation of metastatic cancers. How can
vector-based therapies, posing now more or less as traditional vaccines, be optimized to avoid unintended
RNA-splicing reactions? How can we be assured of the safety of pharmaceutical products that deliberately
breach the most intensive biological barriers of the body (Kowarz et al., 2021)? Currently, we cannot rule
out the possibility that the spike open-reading frame of SARS-CoV-2 can be disrupted by arbitrary
(unpredictable) splicing events when transcribed inside the nucleus, possibly leading to soluble spike protein
variants. The protein content roughly consists of about 2/3 of human and 1/3 of viral origin, together
accounting for about 1,000 different proteins present in a vector DiCoReTh-injection. This also includes
protein impurities that contribute to the strong clinical reactions with flu-like symptoms that are often
observed following vaccination (Krutzke et al., 2021). For compositional analysis of mRNA and vector
therapies represented as “vaccines”, see Seneff and Nigh (2021) and also Broudy and Kyrie (2021).
Both approaches raise ethical concerns as they purport to reduce the living languages of the genome to a
computer-like operating system, supposedly making the software of life fully accessible to genetic
engineers. Based on current knowledge, these novel DiCoReTh-injections urgently need further research as
so-called chromosomal insertions are known to happen to a certain extent, and can have undesirable
effects (Baum et al., 2006).
4
4.0 An Unending Series of Shots and Booster-Boosters?
With these considerations in mind, any efforts to tame or even eliminate (zero-COVID approach) the
spread of SARS-CoV-2 viruses via novel biotechnological tools is an impossible goal to achieve. And even if
it could be achieved, COVID-19 immunity could be lost within months (Seow et al., 2020), making frequent
booster shots an inevitable routine, while at the same time demonstrating the lack of coverage or power of
the prior shots against a rapidly diversifying set of moving targets (Ou et al., 2021; Pachetti et al., 2020). Will
any number of boosters be more effective than the ones already currently being deployed? Experience from
the past has already made it evident that recipients of trivalent inactivated influenza vaccines (TIV) had an
increased risk (4.40) of virologically confirmed non-influenza infections (Cowling et al 2012), and, though
denied by researchers, a surprisingly high rate of interference with embryological development resulting in
congenital defects or fatality to the unborn (Eaton et al., 2018). Especially for non-influenza viruses, the
chances to find both coronavirus and human meta-pneumovirus among vaccinated subjects were
significantly higher (OR = 1.36 and 1.51, respectively) than in unvaccinated individuals (Wolff, 2020).
4
The term “undesirable effects”, like the conventional medical phrase “side effects”, falls somewhat short. From a holistic
therapeutic approach, we are inclined to say that such insertions will ultimately disrupt the natural harmonic gene-sequence
pattern, thus interfering with self-similar properties within the genome (leading to decoherence). Once the normal fractal
pattern is altered, the harmonically interwoven life-processes of the organism as a whole are altered. In cases of some almost
negligible modifications, we may expect disease predispositions, whereas in more consequential ones, aggressive forms of
chronic pathologies eventually resulting in premature deaths are to be expected. In terms of signaling requirements, such
insertions can detune the finely articulated resonance patterns across the organism just as a detuned radio-receiver that is not
perfectly aligned to the transmission frequency generates blurbs, cracks, ditches, and interference, thereby rendering the melody
and its message less interpretable.
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 182
Candidates against the feline coronavirus FIPV (passive vaccination) led to adverse effects with the
consequence that vaccinated cats showed an increased risk of a symptomatic infection compared with cats
that didn’t receive the vaccine (Takano et al., 2019).
Figure 3. Estimation of the effectiveness
of vaccination against influenza
A(H1N1) and influenza A(H3N2) in
three age groups during the 2018/19
season, based on a point estimate and a
95% confidence interval. The
arrowheads indicate a value beyond the
Y-axis shown. FRG (), DK (), UK
(), EU (); (composite figure based
on data from Kissling et al. (2019) and
Buda et al. (2019).
4.1 Is the Notorious Inefficacy of Influenza Vaccines Relevant?
This immediately raises the question of vaccination efficiency (VE), which often is found to be age-
dependent. Data on VE are rather scarce the data available, however, report age-dependent VE against
laboratory-confirmed influenza A(H1N1) for Denmark and the UK (Kissling et al., 2019). A similar age-
dependent trend in VE of laboratory confirmed A(H1N1) and A(H3N2) influenza cases was also
documented in Germany there, the negative VE values for some age-groups are even more striking
(Buda et al., 2019). Figure 3 depicts such an exemplary trend. A negative VE-value implies that no
statistically significant protection of the vaccinated individual against influenza can be demonstrated
compared to unvaccinated people; i.e. in other words, a vaccinated person has a higher risk of contracting
influenza at the same exposure conditions than an unvaccinated individual. Indeed, recent data analysis
regarding DiCoReTh seem to reveal exactly that trend; i.e. that VE against the most recent SARS-CoV-2
strains is fading steadily. In the age groups between 15-24, VE plumets into negative territory even after the
2nd dose (especially for vector-“vaccines”, somewhat less for mRNA “vaccines”) making repeated booster
doses a necessity (see table 2 of Andrews et al., 2021).
4.2 VAERS and the Death Toll of DiCoReTh-Injections
A similar relationship exists for other traditional vaccines. In the case of polio vaccines, for example, it has
been observed that vaccination campaigns triggered polio incidence in regions where the virus was endemic
(wild poliovirus, WPV), while in regions with non-endemic polio, as a result of vaccination there were
circulating vaccine-derived poliovirus cases (cVDPV) that increased steadily over the following years
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 183
(Jenkins et al., 2010; PGEI, 2021). Paradoxically, as we aim to move toward global polio eradication, the
burden of vaccine-induced polio is becoming increasingly important (Lopalco, 2017, Leslie, 2021).
4.3 DiCoReTh-Injection Recipients at Greater Risk of COVID Infection?
In spite of the size of the ongoing experiment, with tens, even hundreds of millions, being injected during
the world-wide SARS-CoV-2 vaccination campaign, it seems as stressed in Figure 4a and 4b that the
novel line of vector-DiCoReTh-injections is resulting in markedly higher fatality rates. This is happening not
5
Austria, Belgium, Cyprus, Denmark, Estonia, Finland, France, Germany (Berlin), Germany (Hesse), Greece, Hungary, Ireland,
Israel, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Slovenia, Spain, Switzerland, UK (England), UK (Northern
Ireland), UK (Scotland), UK (Wales), and Ukraine.
4a
4b
Figure 4a. Top: Cumulative reports of Vaccine Mortality Rate per year. The period of the COVID-19 DiCoReTh-injection
introduction reflects data only till December 24th 2021 (VAERS, 2021).
Figure 4b. Bottom: Graph showing the pooled weekly total number of deaths provided by the 29 European states5
contributing to the EuroMomo registry database within the age group 15-44 years over the last four years. The greyish area
designates the normal fluctuations (±2 z-score units), whereas the dashed red line (z-score of 4) equates to about 200 excess
deaths per week while a score of 6 equates to 300 excess deaths (above the baseline). Observed peaks at the turn from one
year to the subsequent year are attributable to the annual appearance of the flu-season. In 2020/21, that season was regarded
as insignificant (GISRS, 2021), leaving the subsequent rise in registered death cases (denoted by the encircled area) as
attributable most probably to the enforced DeCoReTh campaign (EuroMomo, 2022).
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 184
only among the elderly, but across the broad spectrum of persons being injected (Figure 4a). In the last eight
weeks of 2021, DiCoReTh injections were negatively impacting more people than across the whole history
of the VAERS reports of adverse reactions to traditional vaccines. The contrast was huge even for
DiCoReTh versus the conventional influenza vaccines (EudraVigilence, 2021; VAERS, 2021).
6
While the
efficacy of the current vector-DiCoReTh-injections is still being evaluated (i.e. initially, a relative risk
reduction to contract COVID-19 of 95% for the mRNA DiCoReTh-injections and 67% for vector
DiCoReTh-injections, which translates to an absolute risk reduction of only 0.84-1.2% and 1.3%
respectively (Olliaro et al., 2021), a significant drop in efficiency is already observable (Wadman, 2021; Uriu
et al., 2021; Keehner et al., 2021). With the emergence of the delta and now “omicron” variants, the
proclaimed protection by the novel vector-DiCoReTh-injections is becoming more and more doubtful as
the probability of spreading the virus not only equivalizes in recipients of the experimental DiCoReTh-
injections, but seems likely to greatly surpass infections in unvaccinated persons (Chau et al., 2021). In the
instance of the “delta” variant, the health care professionals studied in the hospital setting had
viral loads of breakthrough Delta variant infection . . . 251 times higher than those of cases infected with old strains
detected between March-April 2020. Time from diagnosis to PCR negative was 833 days (median: 21). Neutralizing
antibody levels after vaccination and at diagnosis of the cases were lower than those in the matched uninfected controls.
There was no correlation between vaccine-induced neutralizing antibody levels and viral loads or the development of
symptoms. . . . Breakthrough Delta variant infections are associated with high viral loads, prolonged PCR positivity, and
low levels of vaccine-induced neutralizing antibodies, explaining the transmission between the vaccinated people (Chau
et al., 2021).
In the case of vector DiCoReTh-injections, this occurs within three months of the last vaccination, whereas
for mRNA DiCoReTh-injections, the waning effect is only slightly higher (Mallapaty, 2021). It can’t be
excluded in the long run that this novel class of DiCoReTh-injections will fail altogether due to continuously
mutating subspecies. From this perspective, mass vaccination does not make sense at all as a large part of
the population is already sufficiently protected by natural infections (Reiss and Bhakdi, 2020).
5.0 Natural Immunity Is Better
As early as 2020, Gomes et al. reached the conclusion that people who have natural immunity are not
susceptible to the virus and therefore do not become sick. Rather, by realistic modelling of available data, a
maximum of 7-18% of the population will become infected with SARS-CoV-2, implying that herd immunity
is achieved already at that level. Hence, indifferent mass vaccination must also be evaluated from this
perspective, as it erodes herd immunity (particularly, as vaccinating young individuals adversely affects their
innate immunity). This is especially relevant since lasting immunity to COVID-19 is suggested with
infections without symptoms and even after mild illness; i.e., the normal rise in antibody levels is a
consequence of infection. Antibody-producing cells are found even 11 months after the onset of initial
6
VAERS data released by the Centers for Disease Control and Prevention (CDC) showed that between December 14 2020 and
August 27, 2021, in the US alone, a total of 650,077 adverse events were reported, including 13,911 deaths out in roughly 357
million doses administered (equivalent to 179 million US-citizens having received two doses), which translates to an adverse
effect rate of 0.36%. EudraVigilence on adverse reactions due to mRNA and the vector “vaccines (May 22, 2021) lists 12,184
fatalities and 1,196,190 injuries.
Moderna:
https://dap.ema.europa.eu/analytics/saw.dll?PortalPages&PortalPath=%2Fshared%2FPHV%20DAP%2F_portal%2FDAP&Action=Navigate&P0=1&P1=eq&P2=%22Line%20Listing%20Objects%22.%22Substan
ce%20High%20Level%20Code%22&P3=1+40983312
Biontech:
https://dap.ema.europa.eu/analytics/saw.dll?PortalPages&PortalPath=%2Fshared%2FPHV%20DAP%2F_portal%2FDAP&Action=Navigate&P0=1&P1=eq&P2=%22Line%20Listing%20Objects%22.%22Substan
ce%20High%20Level%20Code%22&P3=1+42325700
AstraZeneca:
https://dap.ema.europa.eu/analytics/saw.dll?PortalPages&PortalPath=%2Fshared%2FPHV%20DAP%2F_portal%2FDAP&Action=Navigate&P0=1&P1=eq&P2=%22Line%20Listing%20Objects%22.%22Sub
stance%20High%20Level%20Code%22&P3=1+40995439%20
Janssen:
https://dap.ema.europa.eu/analyticsSOAP/saw.dll?PortalPages&PortalPath=%2Fshared%2FPHV%20DAP%2F_portal%2FDAP&Action=Navigate&P0=1&P1=eq&P2=%22Line%20Listing%20Objects%22.%
22Substance%20High%20Level%20Code%22&P3=1+42287887
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 185
symptoms, demonstrating that SARS-Cov-2 infections elicit a strong immune response in humans (Turner
et al., 2021). As Coronaviruses have been around for decades, about one-quarter of people have antibodies
from such precursor versions that can bind to the SARS-CoV-2, thereby neutralizing it quite efficiently, thus
herd immunity has already been established years ago (Jones, 2020). On top of that, it has been shown that
patients with immunoglobulin A (IgA) deficiency do not have a worse prognosis than healthy individuals
(Naito et al., 2020). This, in turn, would indicate that lymphocytes are responsible for the immune reaction
more so than the antibodies, which calls into question vaccination which should induce them.
5.1 Still Being Overlooked Though Known to Be Superior
Throughout the management of the current “pandemic”, natural immunity has been more or less neglected.
The USA, so far, does not recognise any immunity through natural infection, even though the CDC itself
admits some effectiveness of natural immunity after infection. Cohort studies indicate an 80%90%
reduction in incidence for at least 6 months after infection among antibody-positive persons (CDC, 2021b).
Still, the CDC recommends vaccination of this group also without further stipulations (CDC, 2021c). The
question has to be raised why this is the case. Rooted in a firm push-back against the way Sweden and Great
Britain were handling the “pandemic” in the beginning, and subsequently against any quest for so-called
herd immunity without vaccines of some kind, the John Snow Memorandum proclaimed the danger of
trusting natural immunity and dismissed any public health value in it (Alwan et al., 2020). Even the
epidemiological term herd immunity itself started to be frowned upon and politically charged, which
resulted in a general distrust of natural immunity. Fortunately, the EU policies recognize natural immunity
to some degree. Proof of a COVID-19 infection through a positive PCR test, or in some countries with a
more trustworthy serological antibody count, results in a recovered status for a set number of months and
subsequently requires no shot by policy in some EU-states but at least one dose of some DiCoReTh-
injection remains a general requirement for a person to be considered fully vaccinated (EC, 2021b).
Nonetheless, it is noteworthy that the EU policies acknowledge natural immunity to some degree.
5.2 Infected Persons Not Helped by DiCoReTh-Injections
When immunity is acquired through infection, vaccination seems to bring little or no benefit, but it does
bring with it risks associated with its documented side effects (see footnote 4 below) as well as possible
long-term reactions that the DiCoReTh-injection may cause (Bock, 2021). Menni et al (2021) found in their
study, that systemic side effects after vaccination were more common in individuals with previous
infections than among those without known infection. This again shows the problem with the
undifferentiated, blanket approach of the current DiCoReTh-injection campaign. It does not reflect a
thoughtful risk-benefit-analysis and exposes a large group of the population to one or more DiCoReTh-
injections that they do not need, and puts them at risk of adverse side effects while using up DiCoReTh
doses that, if they were helpful at all, could, in principle at least, be beneficial to groups more likely to be
negatively, perhaps severely, impacted by some SARS-CoV-2 variant.
5.3 The Fatality Rate for COVID-19 Greatly Over-Estimated
Relating all these aforementioned aspects to the hypothesized claims that the “pandemic” will result in
outstanding numbers of fatalities, it is further corroborated that SARS-CoV-2 is not the deadly virus as
initially proclaimed, because, in the vast majority of cases, it did not even lead to severe illness and/or
serious sequelae in healthy individuals. Moreover, SARS-CoV-2 under normal circumstances does not come
into contact with the bloodstream. In the case of an intramuscular injection, however, such a transmigration
occurs rather frequently (Hassett et al., 2019). In that case, affected endothelial cells could be stimulated to
synthesize the genetic material and present the spike protein via the MHC-I pathway on their cell surface. In
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 186
capillaries, where blood flow velocity is rather low, this can easily result in lymphocyte interaction (Chen et
al., 2020), leading to tiny, localized blood clots, which ultimately result in micro-thrombosis even up to four
weeks following vaccination (Hafeez et al., 2021). In the case of a previously acquired COVID-19 infection,
CD8 lymphocytes are already present in the blood of the affected individual. Thus, the risk of cross-
reactions after vaccination are real (Grifoni et al., 2020; Sekine et al., 2020; Nelde at al., 2020;). Since cases of
thrombocytopenia have already been described (Zhang et al., 2020c; Lippi et al., 2020), this is a serious
development that is cause for concern, especially in the case of RNA vaccination (Grady, 2021). Therefore,
a SARS-CoV-2 jab is uncalled for (Reiss and Bhakdi, 2020).
5.4 DiCoReTh-Injections for Children and Infants?
Given the emergency approval status granted to these novel DiCoReTh-injections, anyone exposed to one
of them needs to be made aware that he or she is participating in a global field trial equivalent to a phase III-
traditional vaccine safety study.
7
Although as troubling as compulsory vaccination of medical personnel is
as it has been enforced by law in some EU-countries such as Italy (GU, 2021) even more threatening
is the currently planned expansion of the vaccination program to include children, infants, and pregnant
women. The latter seems particularly strange because hardly any COVID-19 cases have been documented in
children so that the risk of mortality in those groups is almost zero from any circulating virus (Ioannidis
2020). The idea to include this share of the population in the vaccination program is a clear indication that
authorities don’t understand this “pandemic” at all. Unfortunately, this will no longer be the case once
children and the unborn babies of pregnant women are exposed in significant numbers to one or more
DiCoReTh-injections. However, currently there are no data to assess the outcome of maternal COVID-19
vaccination on offspring health (Karrow et al., 2021). It is reasonable to suppose that in children the spike
protein can i) bypass the innate immune system, ii) enter the bloodstream, and, given the encapsulating LNP
layer, iii) be even more toxic in children than adults. In such a scenario, the risk-benefit ratio becomes
unreasonable (Kostoff et al., 2021). A study published a year ago emphasizes the risk of contracting acute
and chronic conditions during the first 12 months of post-partum life when all the recommended traditional
vaccines are administered (Hooke and Miller, 2020). Since COVID-19 is not a childhood disease as it
primarily affects the elderly vaccination in the age-group <40 is not at all justified. Given what is already
known of the DiCoReTh-injections deployed in recent months, health specialists and parents should be
cautious. On top of that and according to the hygiene hypothesis, young children should also refrain from
wearing masks or being engaged in excessive hygiene, as such practices are associated with epigenetic
hyperexpression of various genes, which inevitably leads to a weakening of the immune system that can
persist for decades (Olszak et al. 2012).
5.5. Bossche Says Vaccination During a Genuine Pandemic Cannot Work
At a recent plenary lecture at an international vaccine conference, Vanden Bossche (2021) expressed
concern about mass vaccination during a pandemic given the obvious fact that traditional vaccines, as well
as the experimental DiCoReTh-injections, are all designed for prophylactic use. They do not have the power
to kill a disease agent but rather contain all or part of one, or some product of a pathogen, that is supposed
to stimulate antibody production against the actual cause of some targeted disease. As such, according to
Vanden Bossche, vaccines of any type are not an efficient way to control an ongoing pandemic but instead
will lead to vaccine resistance. They may be sensibly deployed to prevent one in the future, but not to halt
7
Why was Israel able to provide this new vaccine to its population so quickly, starting as early as January 2021? The Real-World
Epidemiological Evidence Collaboration signed by Pfizer and the Israeli Ministry of Health provides vaccines for its entire population,
and in return the manufacturer receives an undisclosed payment along with the data on the vaccines safety and efficacy, making
Israel de facto the first large-scale field laboratory (Birnhack, 2021).
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 187
one already in progress. He therefore advised that vaccination should never be used on a large scale where
the population has already been exposed to widespread infection and the challenges to the natural immune
functions already under stress.
His concerns are further supported by observations that the diversity of SARS-CoV-2 antibodies naturally
produced is dampened in the population by mass vaccination (Niesen et al., 2021). That result was also
observed by Chau et al. (2021) who found that “neutralizing antibody levels after vaccination” were lower in
vaccinated health care workers who became infected with a “Delta” variant which they carried at levels 251
times higher than persons infected with a prior, and distinct variant. The implication is that vaccinated
persons may not only have suppressed antibody production against a novel variant of the disease condition
that the “vaccine” supposedly protects them from, but, given the impact of the DiCoReTh-injection itself
they got two doses of the Astra-Zeneca adenovirus, viral vector “vaccine” (the type depicted at the right
hand side of our Figure 2 on page 180) they may become a reservoir for and the source of a new variant
of the targeted disease agent. Significantly, the health workers who had experienced the “breakthrough Delta
variant infection” all became carriers of a variant that was “phylogenetically distinct from the contemporary
Delta variant” that had previously proved to be more infectious than the “Alpha” variant of SARS-CoV-2.
5.6 Artificial Exposure to Viruses Speeds Mutant Production
Regardless of the proclaimed high efficacy by DiCoReTh-injection producers, Bossche’s expressed concern
was rooted in the fact that vaccination on a large scale both accelerates and amplifies viral mutation rates.
That is to say, new variants compared to the original strain have a better chance to increase their reservoir
(see the Chau et al. study) thereby augmenting the viral replication capacity and spread of the new variants.
All of this would turn the current global vaccination campaign into a program for advancing and amplifying
the disease rather than reducing and dampening it. Although viruses cannot think and plan, the humans
manipulating them and the DiCoReTh-injections impacting their downstream transformations and
replications, with regard to the qS-c theory, really can account for a change in viral competencies within an
organism to more rapidly produce and promote infective variants. Such programmed “mutants are,
according to the findings of Chau et al., better able to resist the antibodies produced by multiple exposures
to a DiCoReTh-injection a finding first reported by Farinholt et al. (2021). Moreover, recent data seem to
even attest an opposite effect evidencing an increased risk of infection by the Beta, Gamma, or Delta
variants after full vaccination, regardless of the “vaccine” used (Andeweg et al., 2021).
5.7 Explaining So-Called “Breakthrough” Infections
In addition, one should not forget that any vaccination is an artificially induced infection more suddenly
impacting the whole organism. It is quite unlike the sigmoidal progression of a natural infection, and the
“vaccine”, especially one of the DiCoReTh varieties, does not act at the normal sites of a natural infection
(nose, throat, lungs). Contrary to natural infections, which yield short-lived antibodies to the common cold
viruses, for instance, and life-time natural immunities in others (to measles, chicken-pox, and so forth),
DiCoReTh-injected individuals may be building up replicants of some infectious agent indefinitely and with
unknown long-term consequences. The results of Chau et al. as well as Farinholt et al. suggest that the
antibodies generated to suppress whatever part of the SARS-CoV-2 virus the DiCoReTh-injection generates
in great supply (assuming it works as intended, as it seemed to in health workers studied by Chau et al.) can
stress natural immunity and consequently actually promote and speed up the generation of new variants of
whatever infectious agent, or whatever part of one, the DiCoReTh-injections introduce into the body’s
genetic systems during a period of weakened immunity. All this can potentially render the vaccinated
individuals themselves more susceptible to infections by new variants the so-called “breakthrough”
mutants while at the same time the vaccinated individuals, as seen by Chau et al., become potential
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 188
“super-spreaders” because they are producing a great deal of the new SARS-CoV-2 viral material. As noted
above, this threat scenario played out when DiCoReTh-injected health workers were found to have 251
times more viral load of the delta strain of SARS-CoV-2 than their unvaccinated counterparts (Chau et al.,
2021).
6.0 The “Adjuvant Effect” of LNP Encapsulated DiCoReTh-Injections
It appears that the adjuvant-effect of DiCoReTh-injections is powerful. Whether it involves any named
“adjuvant” in addition to the NLP carrying the mRNA into cells or the DNA induced production of some
variant of the programmed disease component is unknown (Chung et al., 2020), or at least is, according to
Chung et al. (see their “Conclusion” on p. 15532), undeclared by the mRNA “vaccine” manufacturers. They
do not name any specific adjuvants unless polysorbate and PEG are counted as such. However, as already
noted, the mRNA and viral vector DNA products, presently being widely used in the world wide
DiCoReTh-injection experiment, contain viral products encapsulated within the LNPs that can themselves act
as adjuvants (Kim et al., 2021).
6.1 The Long and Perilous History of Adjuvants
The inclusion of well-known adjuvants consisting of aluminium-hydroxide or aluminium phosphate
particles which are easily detectable (Gatti and Montanari, 2015), and are known to cause adverse effects
(Petrik et al., 2007; Tomljenovic & Shaw, 2011; Shaw et al., 2014; Butnaru & Shoenfeld, 2015; Gherardi et
al., 2019; Crépeaux et al., 2020) is particularly relevant for children up to the age of five who will typically
have already been exposed to multiple doses of vaccines containing such adjuvants. All this, before
potentially being exposed to DiCoReTh-injections that are known to have deleterious effects on the
immune systems of healthy adult individuals, much less can those injections be regarded as safe for use in
children with lower body weight and more limited resources for ridding the body of toxicants through liver,
kidney, and lymphatic functions. This younger age group is known already to be prone to greater harm by
aluminum toxicity compared to older, larger, and more mature cohorts (Lyons-Weiler et al., 2020). As an
aside, it is noteworthy that the neurotoxic potential of the aluminum-nanoparticles (Gherardi et al., 2001;
Win-Shwe and Fujimaki, 2011; Cerpa-Cruz et al., 2013) could easily be avoided in currently “mandated”
childhood vaccines by substituting extracts from medical plants that are biologically compatible with human
bodies (Sander et al., 2019) whereas the aluminum adjuvants are absolutely not (Burrell & Exley, 2010; Mold
et al., 2016; Exley, 2017; Masson et al., 2017; Crepeaux et al., 2020). There is no known biologically
compatible uptake of aluminum into living systems (Shaw, Seneff, et al., 2014). As authorities are
increasingly insisting on the use of DiCoReTh-injections in younger and the more vulnerable populations of
children, even infants, there exists an urgent need to take account of known interactions of the polysorbate
and PEG excipient/adjuvants in those experimental injections being added on top of the toxic burden of
previous injections of aluminum adjuvants into individuals known to be more susceptible of immune system
damage than the many adults who have already been injured (Shoenfeld & Aron-Maor, 2000; Wraith et al.,
2003: Molina & Schoenfeld, 2005; Agmon-Levin et al., 2009; Toussirot & Bereau, 2015).
6.2 Blaylock’s “Cytokine Storm” Playing Out
Figures 5a and 5b contain two images along with elemental analysis taken with a field-emission source
operated in environmental SEM mode equipped with electron-backscatter diffraction camera and X-ray
energy drift spectrometer (EDS), which reveal the xenobiotic particles in brain tissue samples from
prematurely deceased newborns. A similar investigation that likewise used environmental electron
microscopy (ESEM) to study the composition of mRNA and vector “vaccines” revealed that these
DiCoReTh-injections contain components that are not mentioned in the instruction leaflet (TSC, 2021). The
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 189
identified substances are known for their bio-incompatibility by adversely affecting blood circulation, and
vascular endothelium, contributing to the formation of thrombi, as well as increasing the risk of
hemorrhaging. Nanoparticles such as graphene, regarded themselves as adjuvants (Xu et al., 2016; Cao,
2020; Chung et al., 2020), are known to induce pro-inflammatory cytokine expression consider Blaylock’s
(2021) “cytokine storm” (also see Fleming, 2021) — and in combination with PEG supposedly to improve
elimination from the body (Palmieri et al., 2019). However, the DiCoReTh-injections are actually designed
to disperse the LNPs and their payloads throughout the body (Kostoff et al., 2021). Graphene oxide used to
induce a biomolecular corona can be toxic as it causes LDH leakage, results in decreased levels of
glutathione and associated peroxides, supresses mitochondrial membrane potential, slows ATP synthesis,
and increases DNA damage (Gurunathan et al, 2019). Such nanomaterials are known to cross the blood
brain barrier, enter the brain, and potentially induce strokes, and/or cerebral hemorrhages, while also
damaging the endothelium of the heart muscle triggering a rise in myocarditis (Mevorach et al., 2021) and
pericarditis cases among the young (Rose et al., 2021), predominantly affecting males (Mevorach et al.,
2021). Indeed, both peri- and myocarditis are the most commonly observed adverse effects among mRNA-
based DiCoReTh-injections amounting to 79.2% and 87.2% respectively (Hajjo et al., 2021).
7.0 Socio-Political Implications and Demographics
Several governments within the EU are still concentrating on and intensifying DiCoReTh-injection
campaigns for people aged 65 years or older (EDCD, 2018). Italy is one of various COVID-19 epicenters
and is not an exception to the continued focus of DiCoReTh-injections for the elderly population (Madl et
al., 2021). Some 20.3% (225,316 of the 1,109,933 inhabitants) of the residents in the COVID-19 hotspot
province of Bergamo were already 65 years or older at the onset of this “pandemic”. A complicating fact for
that elderly population in Bergamo was that during the 20192020 period, 185,000 doses of influenza
vaccine were ordered for this age group (BN, 2019a) a bracket with a vaccination coverage rate of 52.7%
(Mereckiene, 2018). In that same age group, about 118,742 individuals would have received a flu-jab and
Figure 5a. Presence of aluminum
compounds in the brain of
deceased babies. Aluminum
particle most likely aluminum-
hydroxide.
Figure 5b. Debris of aluminum-
phosphate compounds
commonly used as adjuvants in
vaccines.
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 190
34,000 of them (BN, 2019b) would have undergone meningitis vaccination (Madl et al., 2021). Given the
potential for some significant percentage receiving either the flu or meningitis shots, or both of them, it was
to be expected that they would also be more susceptible to COVID-19 infections. Later when the
DiCoReTh-injections were added into the picture, even higher injury rates for those individuals would be
expected (Cowling et al 2012; Wolff, 2020). All this was done in spite of the fact that during the 2019 flu
season according to Eurostat (2020), meningitis vaccinations were already known to be associated with
complications when administered to individuals showing flu-like symptoms. This sort of interactive effect
was not in fact new (Wood et al., 1995; Liu et al., 2017). So, the question arises, did this older population in
Bergamo, especially in the capital city of that province, experience such a high rate of COVID infections
because of the high rate of exposure to artificially injected pathogens known to interact negatively?
7.1 Injection and Infection Rates
Only Spain, Belgium, Ireland, the Netherlands, and the UK score higher than Italy in the percentage of
persons vaccinated and have likewise been hit hard during the COVID-19 waves as seen in a preprint article
(EBMPHET, 2020) relating COVID-19 incidence to vaccination coverage rates (VCRs). According to that
paper, the UK, the Netherlands, Belgium, Spain and Italy (among other countries) reveal a statistically
significant (p <0.05) positive correlation between VCR and the incidence of SARS-CoV-2 infections, as well
as mortality in those aged 65 and up. Similar correlations between VCR and case fatality rate (CFR) have
been noted for Europe in general. The editor of the British Medical Journal (Doshi, 2020a, 2020b) highlights
problems associated with current DiCoReTh-injections as applied in elderly population that have not been
properly addressed: for one, he points out that none of the “vaccine” trials has been designed to achieve a
significant reduction in hospital admissions, intensive care unit treatments, or deaths. Also, he notes that in
the absence of sufficient data analysis for persons in the over-65 age bracket, they should not be forced to
receive the experimental DiCoReTh-injections. Accordingly, we are prompted to ask why are such
experimental DiCoReTh-injections being pre-financed and produced with outrageously aggressive
government funding while the privately owned companies that are developing and producing the
DiCoReTh-injections are raking in profits in the billions of dollars and are protected from any kind of
accountability to the general public the people footing the bill?
7.2 Evident Design Flaws Ignored?
The current global use of the new technology DiCoReTh-injections, all of them operating in the US under
emergency use authorization (EUA) and elsewhere under some equivalent emergency provision, was already
beginning to reveal major design flaws in the form of dramatic “side effects” (Salah and Mehta, 2021) even
when only a small percentage of the world’s population had been vaccinated (EMA, 2021b).
8
Documented
cases of hypothyroidism (Kaur et al., 2021) and premature deaths (EudraVigilence, 2021; VAERS, 2021
see also Figure 4) have not been properly acknowledged or addressed by authorities. Although several
countries in Europe as well as the USA halted and/or restricted use of DiCoReTh-injections to certain
population groups after repeated cases of cerebral venous sinus thrombosis (CVST) were documented in
combination with low levels of blood platelets (thrombocytopenia see Schuchat, 2021; Nicolas, 2021;
EMA, 2021a), the current push for world-wide mass vaccination has overwhelmed reasonable constraints.
While any temporary moratorium on the problematic DiCoReTh-injections would certainly be
recommended by persons looking thoughtfully at findings by independent researchers who do not have
8
Given the steady rise in confirmed myocarditis cases (Gargano et al. 2021) it is very likely that the current class of gene-based
DiCoReTh-injections could lose their currently tentative EUA approval; experience from the past with cyclo-oxygenase-2
(COX-2) inhibitors associated with an increased risk of thrombotic events (Bresalier et al. 2005) have resulted in legal battles in
which the producers of the drug was forced to release billions of dollars in compensation.
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 191
conflicts of interest causing them to prefer certain outcomes above others, all of the foregoing causes us to
raise the question of whether such untested DiCoReTh-injections should be used in any kind of
preventative care. When is it reasonable to experiment with human genetics using procedures known to
produce conditions such as thrombocytopenia, myocarditis, pericarditis, not to mention a host of
autoimmune diseases, and a greater number of deaths reported under the VAERS system than for all the
previous vaccines in all the prior years on record combined?
Conclusions
Genetic DNA vector or mRNA injections, especially those termed DiCoReTh-injections in this paper,
involve substantial risks that cannot be properly assessed without cumulative long-term data, and yet these
so-called “vaccines were associated with significant “side effects” even while they were still in their Warp
Speed developmental phase before 2021. The mass use of these rapidly approved DiCoReTh-injections
raises many questions foremost among them is why adequate safety testing has not been undertaken and
why there has been no open public discussion, much less the sort of debate that renown critics with a
scientific background have persistently initiated (e.g. by Prof. Sucharit Bhakdi and colleagues via their NGO
(MWGFD, 2021), Dr. Wolfgang Wodarg via his multilingual platform (Wodarg, 2021), or Nobel laureates
such as Prof. Luc Montagnier and Prof Michael Levitt (Stecklow & Macaskill, 2021) as well as renowned
lawyers such as Robert F. Kennedy, Jr. (CHD, 2021), and Dr. Reiner Fuellmich (Fuellmich, 2021), just to
name a few. The prevailing tunnel vision, disregarding all warning signs being pointed out consistently by
independent researchers who have no vested interest in outcomes other than wanting themselves and
their children to be safe from medical harms is a dangerous social phenomenon. Such single-minded
pursuit of monetary profits and the usurpation of human rights and freedoms have no place in scientific
circles and especially in medical research.
While the processes of human protein biosynthesis are well understood, the introduction of the DiCoReTh-
injections aimed at manipulating human genetic systems at the level of active mRNA and nuclear DNA may
have already unleashed adverse potentials that are beyond anyone’s control. The precautionary principle
should be paramount here, and as always, the potential to do harm must be weighed against any promised
benefits. The thrombosis cases along with a host of other disease conditions, life-threatening disorders,
and many deaths that are directly attributable to DiCoReTh-injections have already occurred in Europe and
the USA illustrate the drama playing out in real time with the DiCoReTh-injections as the main
protagonists while various governmental power-brokers, corporate media and marketing moguls, as well as
touted “medical experts pull the strings. Even the classical inactivated components in traditional vaccines
are not without risks, especially from the problematic adjuvants, excipients, animal proteins, etc., that are
known to pose short-term and long-term threats. However, the DiCoReTh-injections, because of their
direct involvement in genetic re-writing turned loose inside human bodies, raise the ante exponentially as
Mae-Wan Ho pointed out over the last couple of decades in many of her insightful publications (see Ho,
1999, 2013, 2014). Moreover, the use of a prophylactic strategy after a real world-wide pandemic is well underway
would be like closing the barn door after all the horses are long gone.
DiCoReTh-injections are de facto unsuitable as tools to prevent what has already happened. It has been
feared that mass vaccination is only speeding up SARS-CoV-2 diversification and, thus, ensuring its escape
from all existing preventive measures. Must there be an unending series of booster shots trying to chase
down the SARS-CoV-2 variants that are appearing much faster than the chasing shots and boosters can be
produced? More importantly, how will the hopelessly outdistanced boosters ever catch up with the diversity
of SARS-CoV-2 variants flying like bats from a bottomless pit? In view of all the risks, what compensating
benefits can world-wide DiCoReTh-injections (or some other variety of genetic modifications) really offer?
Where are the benefits? One shot was not enough. According to recent research done at the Francis Crick
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 192
Institute a 5- to 6-fold reduction in neutralizing antibodies in patients with a two-dose mRNA DeCoReTh
injection was observed (see supplement section of Wall et al, 2021). Given this finding and the millions of
(a)
(b)
(c)
Figure 6. Data reported in this figure are from the heavily vaccinated population of Alberta Canada. The time from first dose
(left column) to second dose (right column) of DeCoReTh injections until a COVID-19 diagnosis by age group is on the
time line. Note: the first dose data include people diagnosed as COVID-19 cases prior to the date of their second dose;
(a) top: all cases showing the immediate impact of the 1st injection whereas the delayed impact after the 2nd injection only
became manifest after several months; (b) center: those who were hospitalized here too the time delay is observed after
the 2nd injection; (c) bottom: a similar delayed impact exists for reported deaths from COVID-19 (modified after GoA, 2022).
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 193
DeCoReTh cases pursued so far in the UK alone, one could regard Cole’s prediction with thousands of
emerging endometrial cancer cases as not so far-fetched at all (Wilson, 2021). In other words, two
DeCoReTh injections are not as effective as claimed, but more harmful than just one (see Figure 6), so how
can a series of three shots, four, or an unending series of “boosters” set things right? Also, what ever
happened to the known fact that our natural immune defenses can defeat more than 99% of the infectious
diseases to which we are exposed? Why not concentrate on enhancing natural immunity?
Many age groups are at minuscule risk from COVID-19, and even with high SARS-CoV-2 infection rates
and the multiple variants of the virus that have already been identified, COVID-19 does not appear to have
been significantly more of a risk factor than ordinary flu viruses. Even with all the engineering that went
into promoting this world wide “pandemic”(see Fleming, 2021; also,Kennedy, 2021) — largely ignoring the
precautions by Lipsitsch and Galvani (2014) our natural immune defenses seem capable of handling
everything it has thrown at us. Hundreds of millions have even survived, so far, and seem to have overcome
the extra-special risks from DiCoReTh-injections that were schooled by the decades of research that went
into the gain-of-function research and the spike producing “vaccines” (Fleming, 2021; Kennedy, 2021).
Does the global push for mass vaccination make sense in the fight against the COVID-19 pestilence in light
of the known risks of DiCoReTh-injections? Is the relative low risk to individuals a sufficient basis for
shutting down whole countries, and trying to shut down the entire world? There is also an urgent need for
honest and unbiased data collection and analysis of naturally occurring immunity in the population. Artificial
immunization is certainly a valuable tool if done properly, but it requires a solid scientific basis, and in no
way can justify running rough shod over human rights about what goes into our own bodies. The current
vaccination push, as well as the “zero-COVID” strategy is so far from being any kind of scientific necessity
that it can only qualify as a political preference based on the marketing of pharmaceuticals (Kulldorff et al.,
2020; Broudy, 2021; Broudy and Arakaki, 2020; Broudy and Hoop, 2021).
The need for a more informed approach to the “pandemic” is evident. Consideration of natural immunity
in crafting public health policies is essential and cannot reasonably be seconded to DiCoReTh-injections on
account of the obscene profits they offer to the backgrounded power-brokers. Natural immune powers built
into human beings by our Creator along with certain “unalienable rights” (according to the American
Declaration of Independence) are as real as our bodies are, and are valid wedges with which to chock the
wheels of the fearful promoters of this “pandemic” witness Event201 (2019) with its named participants
as documented and recorded before their arguments can possibly take flight again. We need research,
reasoned analysis, and level-headed debates to put the fear of COVID-19 into clear perspective and to put
the quietus to the absurdly false claim that DiCoReTh-injections are an absolute must. Doing this will ease
financial pressure on developing countries that are currently being driven toward an unnecessary and
incredibly costly DiCoReTh-injection campaign. An open, evidence-based discussion of COVID-policies is
most urgently needed to stop the drift towards politically influenced and market-driven management of
issues,
9
that are scientific in nature.
Conflicts of Interest
The authors have no conflict of interest to declare.
9
The continuing global pandemic is important for investor confidence. There is concern about future demand as the latest wave
of infections declines. Investors worry that the pandemic could be over in 2022, and what then? (Blankenhorn, 2021).
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 194
References
Adiguzel, Y., (2021). Molecular mimicry between SARS-CoV-2 and human proteins. Autoimmunity Reviews, 20(4), 102791.
https://doi.org/10.1016/j.autrev.2021.102791
Agmon-Levin, N., Paz, Z., Israeli, E., & Shoenfeld Y. (2009) Vaccines and autoimmunity. Nat Rev Rheumatol, 5(11):648-52.
https://doi.org/10.1038/nrrheum.2009.196
Alwan, N.A., Burgess, R.A., Ashworth, S., Beale, R., Bhadelia, N., Bogaert, D., Dowd, J., Eckerle, I., Goldman, L.R., Greenhalgh,
T., Gurdasani, D., Hamdy, A., Hanage, W.P., Hodcroft, E.B., Hyde, Z., Kellam, P., Kelly-Irving, M., Krammer, F., Lipsitch,
M., McNally, A., McKee, M., Nouri, A., Pimenta, D., Priesemann, V., Rutter, H., Silver, J., Sridhar, D., Swanton, C.,
Walensky, R.P., Yamey, G., & Ziauddeen, H. (2020). Scientific consensus on the COVID-19 pandemic: we need to act now.
Lancet 396(10260): e71-e72. https://doi.org/10.1016/S0140-6736(20)32153-X. The corresponding “John Snow
Memorandum” is available online https://www.johnsnowmemo.com/john-snow-memo.html (accessed: Feb. 2021)
Andeweg, S.P., Vennema, H., Veldhuijzen, I.K., Smorenburg, N., Schmitz, D., Zwagemaker, F., SeqNeth, Molecular surveillance
group, RIVM COVID-19 Molecular epidemiology group, van Gageldonk-Lafeber, A.B., Chantal, S.H., Reusken REM,
Knol, M.J., & Eggink, D. (2021). Increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared
to Alpha variant in vaccinated individuals. medRxiv: 244530109. https://doi.org/10.1101/2021.11.24.21266735
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O'Connell, A.,
Simons, D., Blomquist, P.B., Dabrera, G., Myers, R., Ladhani, S.N., Amirthalingam, G., Gharbia, S., Barrett, J.C., Elson, R.,
Ferguson, N., Zambon, M., Campbell, C.N.J., Brown, K., Hopkins, S., Chand, M., Ramsay, M., & Lopez Bernal, J. (2021).
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv, 2021.12.14.21267615.
https://doi.org/10.1101/2021.12.14.21267615
Aubrit, F., Perugi, F., Léon, A., Guéhenneux, F., Champion-Arnaud, P., Lahmar, M., & Schwamborn K (2015). Cell substrates for
the production of viral vaccines. Vaccine, 33(44): 5905-5912. https://doi.org/10.1016/j.vaccine.2015.06.110
Arvay, C. (2020). Genetische Impfstoffe gegen COVID-19: Hoffnung oder Risiko? [Genetic Vaccines Against COVID-19: Hope
Or Risk?] Schweiz Ärztezeitung, 101(2728): 862-864. https://doi.org/10.4414/saez.2020.18982
Avci, E., & Abasiyanik, F. (2021). Autoimmune hepatitis after SARS-CoV-2 vaccine: New-onset or flare-up? J Autoimmun 125:
102745. https://doi.org/10.1016/j.jaut.2021.102745
Bahl, K., Senn, J.J., Yuzhakov, O., Bulychev, A., Brito, L.A., Hassett, K.J., Laska, M.E., Smith, M., Almarsson, Ö., Thompson, J.,
Ribeiro, A.M., Watson, M., Zaks, T., & Ciaramella, G. (2017). Preclinical and clinical demonstration of immunogenicity by
mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther, 25(6):1316-1327.
https://doi.org/10.1016/j.ymthe.2017.03.035
Baum, C., Kustikova, O., Modlich, U., Li, Z.X., & Fehse, B. (2006). Mutagenesis and oncogenesis by chromosomal insertion of
gene transfer vectors. Hum Gene Ther , 17(3): 253-263. https://doi.org/10.1089/hum.2006.17.253
Birnhack, M. (2021). Who Controls COVID-Related Medical Data? Copyright and Personal Data. IIC 52: 821824.
Doi: 10.1007/s40319-021-01067-5; related source file: https://govextra.gov.il/media/30806/11221-moh-pfizer-
collaboration-agreement-redacted.pdf (accessed: Feb. 2021)
BL, (2020). Dr. Kary MullisInventor of PCR. Benevolent Lite. https://www.youtube.com/watch?v=7j8STZQWFi4 (accessed:
Dec. 2021)
Blankenhorn, D. (2021). Novavax Stock Needs a Longer Pandemic as Investor Patience Wears Thin. Investor Place (accessed:
Sept. 2021): https://markets.businessinsider.com/news/stocks/novavax-stock-needs-a-longer-pandemic-as-investor-
patience-wears-thin-1030833455
Blaylock, R.L. (2021). Excitotoxicity (immunoexcitotoxicity) as a critical component of the cytokine storm reaction in pulmonary
viral infections, including SARS-CoV-2. International Journal of Vaccine Theory, Practice, and Research, 1(2), 223242.
https://ijvtpr.com/index.php/IJVTPR/article/view/14
Bock, J. (2021). Vaccinating people who have had COVID-19: why doesn’t natural immunity count in the US? BMJ, 374: n2101.
https://doi.org/10.1136/bmj.n2101
BN, (2019a). Vaccino antiinfluenzale: a Bergamo ordinate 185 000 dosi. Bergamo News.
https://www.bergamonews.it/2019/10/21/vaccinazione-antinfluenzale-a-bergamo-ordinate-185-000-dosi-di-
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 195
vaccino/332164/?fbclid=IwAR1glyhj6RQOqOp8YbBf5oLMrknl8P4DyQ-k_GsVicLA-vWuTFwiITSUnzM (accessed: May
2020)
BN, (2019b). Emergenza Meningite, Vaccinate 34mila persone tra Brescia e Bergamo. Bergamo News.
https://www.bsnews.it/2020/01/18/meningite-vaccinate-34mila-persone-tra-brescia-e-
bergamo/?fbclid=IwAR1bsaQy4Ppd21k4WLPkYYMnpiBY5tEtdk5gEH25rZfrGjTDyI_RnxNytNU (accessed: May 2020)
Bresalier, R.S., Sandler, R.S., Quan, H., Bolognese, J.A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A.,
Konstam, M.A., & Baron, J.A. (2005). Adenomatous polyp prevention on Vioxx (APPROVe) trial investigators.
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 352(11):
1092-1102. https://doi.org/10.1056/NEJMoa050493
Broudy, D. (2021). Vaccine development and social control: A psychopathology of impaired reasoning in the global push for mass
compliance. International Journal of Vaccine Theory, Practice, and Research, 2(1), 93124.
https://ijvtpr.com/index.php/IJVTPR/article/view/23
Broudy, D., & Arakaki, M. (2020). Who wants to be a slave? The technocratic convergence of humans and data. Frontiers in
Communication, 5. https://doi.org/10.3389/fcomm.2020.00037
Broudy, D., & Hoop, D. (2021). Messianic mad men, medicine, and the media war on empirical reality: Discourse analysis of
mainstream COVID-19 propaganda. International Journal of Vaccine Theory, Practice, and Research, 2(1), 124.
https://ijvtpr.com/index.php/IJVTPR/article/view/22
Broudy, D., & Kyrie, V. (2021). Syllogistic reasoning demystifies evidence of COVID-19 vaccine constituents. International Journal
of Vaccine Theory, Practice, and Research, 2(1), 149172. https://ijvtpr.com/index.php/IJVTPR/article/view/23
Bruno, R., McCullough, P.A.I., Villa. T,F., Henrion-Caude A, García-Gasca, T., Zaitzeva, G.P., Priester, S., Albarracín, M.J.M.,
Sousa-Escandon, A., Mirones, F.L., Payeras-Cifre, B., Zaragoza-Velilla, A., Borini, L.M., Mas, M., Salazar, R., Schinder, E.,
Yahbes, E.A., Witt, M., Salmeron, M., Fernández, P., Marchesini, M.M., Kajihara, A.J., De La Riva, M.V., Chimeno, P.J.,
Grellet, P.A., Lisdero, M., Mas, P., Baudo, A.J.G., Retamoza, E., Botta, O., Brandolino, C.C., Sciuto, J., Avivar, M.C.,
Castillo, M., Villarroel, P., Poblete-Rojas, E.P., Aguayo, B., Macías-Flores, D.I., Rossell, J.V., Sarmiento, J.C., Andrade-
Sotomayor, V., Stokes-Baltazar, W.R., Cedeño-Escobar, V., Arrúa, U., Farina del Río, A., Campos-Esquivel, T., Callisperis,
P., Barrientos, M.E., Fiala, C., & Acevedo-Whitehouse, K. (2021). SARS-CoV-2 mass vaccination: Urgent questions on
vaccine safety that demand answers from international health agencies, regulatory authorities, governments and vaccine
developers. Authorea, preprint. https://doi.org/10.22541/au.162136772.22862058/v1
Buchbinder, S.P., McElrath, M.J., Dieffenbach, C., & Corey, L. (2020). Use of adenovirus type-5 vectored vaccines: a cautionary
tale. Lancet, 396(10260):e68-e69. https://doi.org/10.1016/S0140-6736(20)32156-5
Buda, S., Preuss, U., Wedde, M., & Duerrwald, R. (2019). Effectiveness of vaccination against seasonal influenza vaccine
effectiveness (Wirksamkeit der Impfung gegen saisonale Influenza Impfeffektivität), In: Report on the Epidemiology of
Influenza in Germany, Season 2018/19 (Bericht zur Epidemiologie der Influenza in Deutschland, Saison 2018/19), Robert
Koch-Institut, Berlin (FRG). https://doi.org/10.25646/6232; https://influenza.rki.de/Saisonberichte/2018.pdf (accessed:
July 2020)
Burrell, S.A.M., & Exley, C. (2010). There is (still) too much aluminium in infant formulas. BMC Pediatrics, 10, 63.
https://doi.org/10.1186/1471-2431-10-63
Burrell, C.J., Howard, C.R., & Murphy, F.A. (2016) Fenner and White’s Medical Virology, 5th ed. Academic Press Elsevier
Publisher, San Diego (CA). ISBN 978-0-12-375156-0
Butnaru, D., & Shoenfeld, Y. (2015). Adjuvants and lymphoma risk as part of the ASIA spectrum. Immunologic Research, 61(12),
7989. https://doi.org/10.1007/s12026-014-8622-0
Cabanillas, B., Akdis, C., & Novak, N. (2020). Allergic reactions to the first COVID19 vaccine: a potential role of Polyethylene
glycol? Allergy 14711. https://doi.org/10.1111/all.14711
Cao, W., He, L., Cao, W., Huang, X., Jia, K., & Dai, J. (2020). Recent progress of graphene oxide as a potential vaccine carrier and
adjuvant. Acta Biomater, 112:14-28. https://doi.org/10.1016/j.actbio.2020.06.009
Cappello, F., Gammazza, A.M., Dieli, F., de Macario E.C., Macario, A.J. (2020). Does SARS-CoV-2 Trigger Stress-Induced
Autoimmunity by Molecular Mimicry? A Hypothesis. J Clin Med, 9(7): 2038. https://doi.org/10.3390/jcm9072038
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 196
CDC, (2020). Weekly Updates by Select Demographic and Geographic Characteristics Provisional Death Counts for
Coronavirus Disease 2019 (COVID-19). Center for Disease Control. Centers for Disease and Control Prevention.
https://www.cdc.gov/nchs/nvss/vsrr/COVID_weekly/index.htm (accessed: June 2020).
CDC, (2021a). Emerging SARS-CoV-2 Variants” Centers for Disease Control and Prevention.
https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html
(accessed: Jan. 2020)
CDC, (2021b). Development of Antibodies and Immunity. https://www.cdc.gov/coronavirus/2019-
ncov/lab/resources/antibody-tests-guidelines.html (accessed: Sept. 2021)
CDC, (2021c). Interim Guidelines for COVID-19 Antibody Testing. https://www.cdc.gov/coronavirus/2019-
ncov/lab/resources/antibody-tests-guidelines.html (accessed: Sept. 2021)
Chang, M.C., Hur, J., & Park, D. (2020). Interpreting the COVID-19 Test Results: A Guide for Physiatrists. Am J Phys Med
Rehabil, 99(7): 583-585. https://doi.org/10.1097/PHM.0000000000001471
Chau, N.V.V., Ngoc, N.M., Nguyet, L.A., Quang, V.M., Ny, N.T.H., Khoa, D.B., Phong, N.T., Toan, L.M., Hong, N.T.T., Tuyen,
N.T.K., Phat, V.V., Nhu, L.N.T., Truc, N.H.T., That, B.T.T., Thao, H.P., Thao, T.N.P., Vuong, V.T., Tam, T.T.T., Tai,
N.T., Bao, H.T., Nhung, H.T.K., Minh, N.T.N., Tien, N.T.M., Huy, N.C., Choisy, M., Man, D.N.H., Ty, D.T.B., Anh, N.T.,
Uyen, L.T.T., Tu, T.N.H., Yen, L.M., Dung, N.T., Hung, L.M., Truong, N.T., Thanh, T.T., Thwaites, G., & Tan, L.V.
(2021). An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers
in Vietnam. E-Clinical Medicine, 41: 101143. https://doi.org/10.1016/j.eclinm.2021.101143
CHD (2021). Ending childhood health epidemics. Children's Health Defense. https://childrenshealthdefense.org/ (accessed:
Dec. 2021)
Chen YY, Syed AM, MacMillan P, Rocheleau JV, Chan WCW (2020) Flow rate affects nanoparticle uptake into endothelial cells.
Adv Mater, 32(24): e1906274. https://doi.org/10.1002/adma.201906274
Chen, Y., Xu, Z., Wang, P., Li, X.M., Shuai, Z.W., Ye, D.Q., & Pan, H.F. (2021) New-onset autoimmune phenomena post-
COVID-19 vaccination. Immunology, [ahead of print]. https://doi.org/10.1111/imm.13443
Chung, Y.H., Beiss, V., Fiering, S.N., & Steinmetz, N.F. (2020). COVID-19 vaccine frontrunners and their nanotechnology
design. ACS Nano, 14(10), 1252212537. https://doi.org/10.1021/acsnano.0c07197 Full text PDF 2021 available at
https://pubs.acs.org/doi/pdf/10.1021/acsnano.0c07197
Cerpa-Cruz, S., Paredes-Casillas, P., Landeros-Navarro, E., Bernard-Medina, A.G., Martínez-Bonilla, G., & Gutiérrez-Ureña, S.
(2013). Adverse events following immunization with vaccines containing adjuvants. Immunol Res,. 56(2-3): 299-303.
https://doi.org/10.1007/s12026-013-8400-4
Chiu, W.J., Chen, Y.C., Huang, C.C., Yang, L., Yu, J., Huang, S.W., & Lin, C.H. (2021). Iron hydroxide/oxide-reduced graphene
oxide nanocomposite for dual-modality photodynamic and photothermal therapy in vitro and in vivo. Nanomaterials, 11(8),
1947. https://doi.org/10.3390/nano11081947
CI, (2020). Province of Bergamo and city of Bergamo. Census Data from 2016. Comuni Italiani. http://www.comuni-
italiani.it/016/index.html (accessed: May 2020)
Coors, E.A., Seybold, H., Merk, H.F., & Mahler, V. (2005). Polysorbate 80 in medical products and nonimmunologic
anaphylactoid reactions. Ann Allergy Asthma Immunol, 95(6): 593-599. https://doi.org/10.1016/S1081-1206(10)61024-1
Cowling, B.J., Fang, V.J., Nishiur, H., Chan, K.H., Ng, S., Ip, D.K.M., Chiu, S.S., Leung, G.M., & Peiris, J.S.M. (2012). Increased
risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine. CID, 54: 1778-1783.
https://doi.org/10.1093/cid/cis307
Crépeaux, G., Authier, F.J., Exley, C., Luján, L., & Gherardi, R.K. (2020). The role of aluminum adjuvants in vaccines raises issues
that deserve independent, rigorous and honest science. J Trace Elem Med Biol, 62:126632.
https://doi.org/10.1016/j.jtemb.2020.126632
Desfarges, S., & Ciuffi, A. (2012). Viral integration and consequences on host gene expression. In: Witzany, G. (ed) Viruses:
Essential Agents of Life, 147175. Springer, Dodrecht (NL). https://doi.org/10.1007/978-94-007-4899-6_7
De Melo, G.D., Lazarini, F., Larrous, F., Feige, L., Kornobis, E., Levallois, S., Marchio, A., Kergoat, L., Hardy, D., Cokelaer, T.,
Pineau, P., Lecuit, M., Lledo, P.M., Changeux, J.P., & Bourhy, H. (2021). Attenuation of clinical and immunological
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 197
outcomes during SARS-CoV-2 infection by ivermectin. EMBO Mol Med, 13(8):e14122.
https://doi.org/10.15252/emmm.202114122
deVrieze, J. (2021). Pfizer’s vaccine raises allergy concerns. Science 371(6524): 10-11.
https://doi.org/10.1126/science.371.6524.10
Doerfler, W. (2021). Adenoviral vector DNA- and SARS-CoV-2 mRNA-based COVID-19 vaccines: Possible integration into the
human genome are adenoviral genes expressed in vector-based vaccines? Virus Res, 302: 198466.
https://doi.org/10.1016/j.virusres.2021.198466
Dotan, A., Muller, S., Kanduc, D., David, P., Halpert, G., & Shoenfeld, Y. (2021). The SARS-CoV-2 as an instrumental trigger of
autoimmunity. Autoimmun Rev, 20(4):102792. https://doi.org/10.1016/j.autrev.2021.102792
Doshi, P. (2020a). COVID-19 vaccine trial protocols released. BMJ, 371: m4058. https://doi.org/10.1136/bmj.m4058
Doshi, P. (2020b). Will COVID-19 vaccines save lives? Current trials aren’t designed to tell us. BMJ, 371: m4037.
https://doi.org/10.1136/bmj.m4037
Eaton, A., Lewis, N., Fireman, B., Hansen, J., Baxter, R., Gee, J., & Klein, N. P. (2018). Birth outcomes following immunization
of pregnant women with pandemic H1N1 influenza vaccine 20092010. Vaccine, 36(19), 27332739.
https://doi.org/10.1016/j.vaccine.2017.08.080
EBMPHET Consortium, (2020.) COVID-19 Severity in Europe and the USA: Could the Seasonal Influenza Vaccination Play a
Role? doi: 10.2139/ssrn.3621446. https://ssrn.com/abstract=3621446 (accessed: June 2020)
EC, (2021a). Commission identifies five promising candidate therapeutics. European Comission Press Release 29th June 2021;
https://ec.europa.eu/commission/presscorner/detail/en/ip_21_3299 (accessed: June 2021)
EC, (2021b). Questions and Answers EU Digital COVID certificate.
https://ec.europa.eu/commission/presscorner/detail/en/QANDA_21_2781 (accessed: Sept. 2021)
ECDC, (2021). Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA first update. European
Centre for Disease Prevention and Control; https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-risk-
related-to-spread-of-new-SARS-CoV-2-variants-EU-EEA-first-update.pdf (accessed: Feb. 2021)
EMA, (2021a). AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low
blood platelets. European Medical Agency. https://www.ema.europa.eu/en/news/astrazenecas-COVID-19-vaccine-ema-
finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood (accessed: Feb. 2021)
EMA, (2021b). Online access to suspected side-effect reports. European Medical Agency.
http://www.adrreports.eu/de/search_subst.html search for Covid-19 (accessed: Feb. 2020)
EMA, (2021c). Assessment report: COVID-19 mRNA Biontec. Procedure No. EMEA/H/C/005735/0000.
https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty (accessed: Feb. 2021)
EMA, (2021d). Assessment report: COVID-19 Vaccine Moderna. Procedure No. EMEA/H/C/005791/0000.
https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax (accessed: Feb. 2021)
EMA, (2021e). Assessment report: COVID-19 Vaccine Astrazeneca. Procedure No. EMEA/H/C/005675/0000.
https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-COVID-19-vaccine-astrazeneca (accessed:
June 2021)
EMA, (2021f). Assessment report: COVID-19 Vaccine Janssen. Procedure No. EMEA/H/C/005737/0000
https://www.ema.europa.eu/en/medicines/human/EPAR/COVID-19-vaccine-janssen (accessed: March 2021)
EudraVigilence, (2021). European database of suspected adverse drug reaction reports.
https://www.adrreports.eu/en/search.html (accessed June 2021)
EuroMomo, (2022). European monitoring of excess mortality for public health action. https://euromomo.eu/graphs-and-maps/
(accessed: Jan. 2022)
EuroStat, (2020). Vaccination against influenza of population aged 65 and over. European Commission.
https://ec.europa.eu/eurostat/web/products-datasets/-/hlth_ps_immu (accessed: May 2020)
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 198
Event201, (2019). A pandemic exercise to illustrate preparedness efforts. Media event hosted by Johns Hopkins Blumberg School
of Public Health, World Economic Forum, & Bill and Melinda Gates Foundation. (2019, October 18).
https://centerforhealthsecurity.org/event201/ (accessed Dec. 2021)
Exley, C. (2017). Aluminum should now be considered a primary etiological factor in Alzheimer’s disease. Journal of Alzheimer’s
Disease Reports, 1(1), 2325. https://doi.org/10.3233/ADR-170010
Farinholt, T., Doddapaneni, H., Qin, X., Menon, V., Meng, Q., Metcalf, G., Chao, H., Gingras, M.C., Avadhanula, V., Farinholt,
P., Agrawal, C., Muzny, D.M., Piedra, P.A., Gibbs, R.A., & Petrosino, J. (2021) Transmission event of SARS-CoV-2 delta
variant reveals multiple vaccine breakthrough infections. BMC Med, 19(1): 255. https://doi.org/10.1186/s12916-021-02103-4
Fleming, D.R.M. (2021). Is COVID-19 a Bioweapon?: A Scientific and Forensic investigation. Skyhorse Publishing (NY). ISBN 978-1-
5107-7019-5
Fuellmich R (2021) Internationale Rechtsanwaltskanzlei fuer Verbraucherschutz und Medizinrecht (Int. Law office for consumer
protection and medical law). https://www.fuellmich.com/ (accessed: Dec. 2021)
Garçon, N., Vaughn, D. W., & Didierlaurent, A. M. (2012). Development and evaluation of AS03, an Adjuvant System containing
α-tocopherol and squalene in an oil-in-water emulsion. Expert Review of Vaccines, 11(3), 349366.
https://doi.org/10.1586/erv.11.192
Gardner, L., Dong, E., CSSE (2021). The COVID-19 Testing Insight Initiative. Coronavirus Resource Center. Center for Systems
Science and Engineering at John Hopkins University. (accessed 20 Aug. 2021)
Gargano, J.W., Wallace, M., Hadler, S.C., Langley, G., Su, J.R., Oster, M.E., Broder, K.R., Gee, J., Weintraub, E., Shimabukuro,
T., Scobie, H.M., Moulia, D., Markowitz, L.E., Wharton, M., McNally, V.V., Romero, J.R., Talbot, H.K., Lee, G.M., Daley,
M.F., & Oliver, S.E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients:
Update from the Advisory Committee on Immunization Practices - United States, MMWR Morb Mortal Wkly Rep, 70(27):
977-982. https://doi.org/10.15585/mmwr.mm7027e2
Gatti, A., & Montanari, S. (2015). Case studies in Nanotoxicology and Particle toxicology. Akademic Press Elsevier Publisher, London
(UK); ISBN 9-780-128-01215-4
Gherardi, R.K., Coquet, M., Cherin, P., Belec, L., Moretto, P., Dreyfus, P.A., Pellissier, J.F., Chariot, P., & Authier, F.J. (2001).
Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain,
124(Pt 9): 1821-1831. https://doi.org/10.1093/brain/124.9.1821
Gherardi, R. K., Crépeaux, G., & Authier, F.-J. (2019). Myalgia and chronic fatigue syndrome following immunization:
Macrophagic myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune
system. Autoimmunity Reviews, 18(7), 691705. https://doi.org/10.1016/j.autrev.2019.05.006
GISRS (2021) Influenza Laboratory Surveillance Information provided by the Global Influenza Surveillance and Response
System, WHO. https://apps.who.int/flumart/Default?ReportNo=10 (accessed Dec. 2021)
GoA, (2021). COVID-19 Alberta statistics. Interactive aggregate data on COVID-19 cases in Alberta. Government of Alberta
(CDN). https://www.alberta.ca/stats/covid-19-alberta-statistics.htm#vaccine-outcomes (accessed Jan. 2022). As of 14th of
Jan. 2022 the interactive chart section is no longer available on the GoA-website, repository data access is only possible via
the web-archive; https://web.archive.org/web/20220114005412/https://www.alberta.ca/stats/covid-19-alberta-
statistics.htm#vaccine-outcomes (accessed Jan. 2022)
Goldman, S., Bron, D., Tousseyn, T., Vierasu, I., Dewispelaere, L., Heimann, P., Cogan, E., & Goldman, M. (2021). Rapid
progression of angioimmunoblastic T Cell lymphoma following BNT162b2 mRNA vaccine booster shot: a case report.
Frontiers in Medicine, 8:798095. https://doi.org/10.3389/fmed.2021.798095
Gomes, M.G.M., Corder, R.M., King, J.G., Langwig, K.E., Souto-Maior, C., Carneiro, J., Goncalves, G., Penha-Goncalves, C.,
Ferreira, M.U., & Aguas, R. (2020). Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd
immunity threshold. medRxiv, 2020.04.27.20081893. https://doi.org/10.1101/2020.04.27.20081893
Grady, D. (2021). A Few Covid Vaccine Recipients Developed a Rare Blood Disorder, The New York Times.
https://www.nytimes.com/2021/02/08/health/immune-thrombocytopenia-COVID-vaccine-blood.html (accessed: Feb.
2021)
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 199
Grenfell, B.T., Pybus, O.G., Gog, J.R., Wood, J.L., Daly, J.M., Mumford, J.A., & Holmes, E.C. (2004). Unifying the
epidemiological and evolutionary dynamics of pathogens. Science, 303(5656): 327-332.
https://doi.org/10.1126/science.1090727
Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings, S.A., Sutherland, A., Premkumar, L.,
Jadi, R.S., Marrama, D., de Silva, A.M., Frazier, A., Carlin, A.F., Greenbaum, J.A., Peters, B., Krammer, F., Smith, D.M.,
Crotty, S., & Sette, A. (2020). Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease
and unexposed individuals. Cell, 181(7):1489-1501.e15. https://doi.org/10.1016/j.cell.2020.05.015
GU, (2021). Misure urgenti per il contenimento dell'epidemia da COVID-19, in materia di vaccinazioni anti SARS-CoV-2, di
giustizia e di concorsi pubblici. (21G00056). Urgent measures for the containment of the epidemic of COVID-19, in the
field of vaccinations against SARS-CoV-2, justice and public sector. Gazzetta Ufficiale Serie Generale n.79 del 01-04-2021
https://www.gazzettaufficiale.it/eli/id/2021/04/01/21G00056/sg (accessed: May 2021)
Gurunathan, S., Arsalan-Iqbal, M., Qasim, M., Park, C.H., Yoo, H., Hwang, J.H., Uhm, S.J., Song, H., Park, C., Do, J.T., Choi, Y.,
Kim, J.H., & Hong, K. (2019). Evaluation of graphene oxide induced cellular toxicity and transcriptome analysis in human
embryonic kidney cells. Nanomaterials (Basel). 9(7): 969. https://doi.org/10.3390/nano9070969
Guzik, T.J., Mohiddin, S.A., Dimarco, A., Patel, V., Savvatis, K., Marelli-Berg, F.M., Madhur, M.S., Tomaszewski, M., Maffia, P.,
D'Acquisto, F., Nicklin, S.A., Marian, A.J., Nosalski, R., Murray, E.C., Guzik, B., Berry, C., Touyz, R.M., Kreutz, R., Wang,
D.W., Bhella, D., Sagliocco, O., Crea, F., Thomson, E.C., & McInnes, I.B. (2020) COVID-19 and the cardiovascular system:
implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res, 116(10): 1666-1687.
https://doi.org/10.1093/cvr/cvaa106
Haberecker, M., Schwarz, E.I., Steiger, P., Frontzek, K., Scholkmann, F., Zeng, X., Höller, S., Moch, H., & Varga, Z. (2021).
Autopsy-based pulmonary and vascular pathology: pulmonary endotheliitis and multi-organ involvement in COVID-19
associated deaths. Respiration, 1-11. https://doi.org/10.1159/000518914
Hajjo, R., Sabbah, D.A., Bardaweel, S.K., & Tropsha, A. (2021). Shedding the light on post-vaccine myocarditis and pericarditis in
COVID-19 and non-COVID-19 vaccine recipients. Vaccines (Basel), 9(10):1186. https://doi.org/10.3390/vaccines9101186
Hassett, K.J., Benenato, K.E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B.M., Ketova,
T., Mihai, C., Lynn, A., McFadyen, I., Moore, M.J., Senn, J.J., Stanton, M.G., Almarsson, Ö., Ciaramella, G., & Brito, L.A.
(2019). Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids, 15:1-
11. https://doi.org/10.1016/j.omtn.2019.01.013
Hasson, S., Al-Busaidi, J., & Sallam, T. (2015). The past, current, and future trends in DNA vaccine immunisations. Asian Pac J
Trop Biomed, 5(5): 344-353. https://doi.org/10.1016/S2221-1691(15)30366-X
Hirose, S., Hara, M., Koda, K., Natori, N., Yokota, Y., Ninomiya, S., & Nakajima, H. (2021). Acute autoimmune transverse
myelitis following COVID-19 vaccination: A case report. Medicine (Baltimore). 100(51): e28423.
https://doi.org/10.1097/MD.0000000000028423
Ho, M.-W. (1999). Genetic Engineering, Dream or Nightmare? The Brave New World of Bad Science and Big Business, 2nd ed. Gateway
Books, Dublin (IRL). ISBN 0-8264-1257-2
Ho, M.-W. (2013). The new genetics and natural versus artificial genetic modification. Entropy, 15(11), 47484781.
https://doi.org/10.3390/e15114748
Ho, M.-W. (2014). Illuminating water and life. Entropy, 16(9), 48744891. https://doi.org/10.3390/e16094874
Hsee, C.K., & Ruan, B. (2016). The Pandora Effect: The power and peril of curiosity. Psychological Science, 1:8.
https://doi.org/10.1177/0956797616631733
Hooker, B.S., & Miller, N.Z. (2020). Analysis of health outcomes in vaccinated and unvaccinated children: Developmental delays,
asthma, ear infections and gastrointestinal disorders. SAGE Open Med, 8: 2050312120925344.
https://doi.org/10.1177/2050312120925344
Hafeez, M.U., Ikram, M., Shafiq, Z., Sarfraz, A., Sarfraz, Z., Jaiswal, V., Sarfraz, M., Chérrez-Ojeda, I. (2021). COVID-19
Vaccine-Associated Thrombosis with Thrombocytopenia Syndrome (TTS): A Systematic Review and Post Hoc Analysis.
Clin Appl Thromb Hemost, 27:10760296211048815. https://doi.org/10.1177/10760296211048815
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 200
Inserra, F., Tajer, C., Antonietti, L., Mariani, J., Ferder, L., & Manucha, W. (2021). Vitamin D supplementation: An alternative to
enhance the effectiveness of vaccines against SARS-CoV-2? Vaccine, 39(35): 4930-4931.
https://doi.org/10.1016/j.vaccine.2021.07.031
Ioannidis, J.P.A. (2020). Infection fatality rate of COVID-19 inferred from seroprevalence data. Bulletin of the WHO, 99(1): 19-
33F. https://doi.org/10.2471/BLT.20.265892
Iwasaki, A., & Yang, Y. (2020). The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol, 20(6):
339-341. https://doi.org/10.1038/s41577-020-0321-6
Jackson, L.A., Anderson, E.J., Rouphael, N.G., Roberts, P.C., Makhene, M., Coler, R.N., McCullough, M.P., Chappell, J.D.,
Denison, M.R., Stevens, L.J., Pruijssers, A.J., McDermott, A., Flach, B., Doria-Rose, N.A., Corbett, K.S., Morabito, K.M.,
O’Dell, S., Schmidt, S.D., Swanson, P.A., Padilla, M., Mascola, J.R., Neuzil, K.M., Bennett, H., Sun, W., Peters, E.,
Makowski, M., Albert, J., Cross, K., Buchanan, W., Pikaart-Tautges, R., Ledgerwood, J.E., Graham, B.S., & Beigel, J.H.
(2020). An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med, 2022483.
https://doi.org/10.1056/NEJMoa2022483
Janiaud, P., Hemkens, L.G., & Ioannidis, J.P.A. (2021). Challenges and lessons learned from COVID-19 trials - should we be
doing clinical trials differently? Can J Cardiol, S0828-282X(21)00285-3. doi: 10.1016/j.cjca.2021.05.009
Jenkins, H.E., Aylward, R.B., Gasasira, A., Donnelly, C.A., Mwanza, M., Corander, J., Garnier, S., Chauvin, C., Abanida, E., Pate,
M.A., Adu, F., Baba, M., & Grassly, N.C. (2010). Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J
Med, 362(25): 2360-9. https://doi.org/10.1056/NEJMoa0910074
Jiang, H., & Mei, Y.F. (2021). SARS-CoV-2 spike impairs DNA damage repair and inhibits V(D)J recombination in vitro. Viruses,
13(10):2056. https://doi.org/10.3390/v13102056
Jiang, S. (2020). Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature, 579: 321.
https://doi.org/10.1038/d41586-020-00751-9
Jones, N. (2020). How COVID-19 is changing the cold and flu season. Nature, 588(7838): 388-390.
https://doi.org/10.1038/d41586-020-03519-3
Karrow, N.A., Shandilya, U.K., Pelech, S., Wagter-Lesperance, L., McLeod, D., Bridle, B., & Mallard, B.A. (2021) Maternal
COVID-19 Vaccination and Its Potential Impact on Fetal and Neonatal Development. Vaccines (Basel). 18;9(11): 1351.
https://doi.org/10.3390/vaccines9111351
Kaur, U., Ojha, B., Pathak, B.K., Singh, A., Giri, K.R., Singh, A., Das, A., Misra, A., Yadav, A.K., Kansal, S., & Chakrabarti, S.S.
(2021). A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in
healthcare workers- first results from India. E Clinical Medicine, 38:101038. https://doi.org/10.1016/j.eclinm.2021.101038
Keehner, J., Horton, L.E., Binkin, N.J., Laurent, L.C., Pride, D., Longhurst, C.A., Abeles, S.R., & Torriani, F.J. (2021). Resurgence
of SARS-CoV-2 infection in a highly vaccinated health system workforce. N Engl J Med, 2021 ahead of print;
https://doi.org/10.1056/NEJMc2112981
Kennedy, R. F., Jr. (2021). The Real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. Skyhorse
Publishing (NY). ISBN 978-1-5107-6680-8
Kim, D., Wu, Y., Shim, G., & Oh, Y.-K. (2021). Lipid nanoparticle-mediated lymphatic delivery of immunostimulatory nucleic
acids. Pharmaceutics, 13(4), 490. https://doi.org/10.3390/pharmaceutics13040490
Kim, M.A., Lee, Y.W., Kim, S.R., Kim, J.H., Min, T.K., Park, H.S., Shin, M., Ye, Y.M., Lee, S., Lee, J., Choi, J.H., Jang, G.C., &
Chang, Y.S. (2021). COVID-19 vaccine-associated anaphylaxis and allergic reactions: consensus statements of the KAAACI
Urticaria/Angioedema/Anaphylaxis Working Group. Allergy Asthma Immunol Res, 13(4):526-544.
https://doi.org/10.4168/aair.2021.13.4.526
Kissling, E., Rose, A., Emborg, H.D. Gherasim, A., Pebody, R., Pozo, F., Trebbien, R., Mazagatos, C., Whitaker, H., Valenciano,
M., European IVE group (2019). Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to
January 2019. Euro Surveil, 24(8): 1900121. https://doi.org/10.2807/1560-7917.ES.2019.24.1900121
Kostoff, R.N., Calina, D., Kanduc, D., Briggs, M.B., Vlachoyiannopoulos, P., Svistunov, A.A., & Tsatsakis, A. (2021). Why are we
vaccinating children against COVID-19? Toxicol Rep. 8: 1665-1684. https://doi.org/10.1016/j.toxrep.2021.08.010
Kowarz, E., Krutzke, L., Reis, J., Bracharz, S., Kochanek, S., & Marschalek, R. (2021). Vaccine-induced COVID-19 mimicry”
syndrome: splice reactions within the SARS-CoV-2 spike open reading frame result in spike protein variants that may cause
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 201
thromboembolic events in patients immunized with vector-based vaccines. Nature-portfolio [preprint]
https://doi.org/10.21203/rs.3.rs-558954/v1
Krutzke, L., Roesler, R., Wiese, S., & Kochanek, S. (2021). Process-related impurities in the ChAdOx1 nCov-19 vaccine. Nature-
portfolio [preprint] https://doi.org/10.21203/rs.3.rs-477964/v1
Kucirka, L.M., Lauer, S.A., Laeyendecker, O., Boon, D., & Lessler, J. (2020). Variation in False-Negative Rate of Reverse
Transcriptase Polymerase Chain ReactionBased SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med, M20-1495.
https://doi.org/10.7326/M20-1495
Kulldorff, M., Gupta, S., & Bhattacharya, J. (2020) Great Barrington Declaration. https://gbdeclaration.org/ (accessed: Feb.
2021)
Lee, W.S., Wheatley, A.K., Kent, S.J DeKosky, B.J. (2020). Antibody-dependent enhancement and SARS-CoV-2 vaccines and
therapies. Nat Microbiol, 5(10): 1185-1191. https://doi.org/10.1038/s41564-020-00789-5
Lessells, R.J. (2021). SARS-CoV-2 variants of concern: the knowns and unknowns. Anaesthesia Critical Care & Pain Medicine,
https://doi.org/10.1016/j.accpm.2021.100868
Leslie, R. (2021). How COVID hurt the fight against other dangerous diseases. Nature, 592: 502-504.
https://doi.org/10.1038/d41586-021-01022-x
Lippi, G., Plebani, M., & Henry, B.M. (2020). Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19)
infections: A meta-analysis. Clin Chim Acta, 506:145-148. https://doi.org/10.1016/j.cca.2020.03.022
Lipsitch M, Galvani AP (2014) Ethical Alternatives to Experiments with Novel Potential Pandemic Pathogens. PLoS Med 11(5):
e1001646. https://doi.org/10.1371/journal.pmed.1001646
Livny, A. (2021). The Testimonies Project testimonies after Covid-19 vaccination. https://www.vaxtestimonies.org/en/
(accessed: Sept. 2021)
Liu, S., Wang, J., Liu, Y., Xu, Y., Che, X., Gu, W., Du, J., Zhang, X., & Xu, E. (2017). Survey of contraindications in children's
routine vaccination in Hangzhou, China. Hum Vacc Immunother, 13(7):1539-1543.
https://doi.org/10.1080/21645515.2017.1304868
Loffredo, J. (2021). British Funeral Director Tells RFK, Jr. About Fear, Propaganda and COVID Vaccine Deaths During Early
Days of Pandemic. Children’s Health Defense. https://childrenshealthdefense.org/defender/rfk-jr-podcast-john-olooney-fear-
propaganda-COVID-vaccine-deaths/ (accessed: Dec. 2021)
Lopalco, P.L. (2017). Wild and vaccine-derived poliovirus circulation, and implications for polio eradication. Epidemiol Infect,
145(3): 413-419. https://doi.org/10.1017/S0950268816002569
Lopez-Leon, S., Wegman-Ostrosky, T., Perelman, C., Sepulveda, R., Rebolledo, P.A., Cuapio, A., & Villapol, S. (2021). More than
50 long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv [preprint]: 2021.01.27.21250617.
https://doi.org/10.1101/2021.01.27.21250617
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020). Developing COVID-19 vaccines at pandemic speed. N Engl J Med,
382:1969-1973; https://doi.org/10.1056/NEJMp2005630
Lyons-Weiler, J. (2020). Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via
autoimmunity. J Transl Autoim, 3: 100051. https://doi.org/10.1016/j.jtauto.2020.100051
Lyons-Weiler, J., McFarland, G., & La Joie, E. (2020). Impact of catch-up vaccination on aluminum exposure due to new laws
and post social distancing. J Trace Elem Med Biol, 62:126649. https://doi.org/10.1016/j.jtemb.2020.126649
Madl, P., Arvay, C., Gatti, A., Giuliani, L., Lettner, H. (2021). Air Pollution, SARS-CoV-2 and the Wider Implications - An
Overview of Recent Events with a Focus on Italy. Aerosol Air Qual. Res, 21, 200438. https://doi.org/10.4209/aaqr.200438
Mallapaty, S. (2021). COVID vaccines cut the risk of transmitting Delta - but not for long. Nature,
https://doi.org/10.1038/d41586-021-02689-y
Mansuriya, B.D., & Altintas, Z. (2021). carbon dots: classification, properties, synthesis, characterization, and applications in
health care-an updated review (2018-2021). Nanomaterials, 11(10), 2525. https://doi.org/10.3390/nano11102525
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 202
Masson, J.D., Crépeaux, G., Authier, F.J., Exley, C., & Gherardi, R.K. (2017). [Critical analysis of reference studies on aluminium-
based adjuvants toxicokinetics]. Annales Pharmaceutiques Francaises, 75(4), 245256.
https://doi.org/10.1016/j.pharma.2017.04.004
Mathieu, E., Ritchie, H., Ortiz-Ospina, E., Roser, M., Hasell, J., Appel, C., Giattino, C., & Ortiz-Ospina, E. (2021). A global
database of COVID-19 vaccinations. Nat Hum Behav 5: 947-953. doi: 10.1038/s41562-021-01122-8; Data on COVID-19
(coronavirus) vaccinations by Our World in Data, accessible: https://github.com/owid/COVID-19-
data/tree/master/public/data/vaccinations
McCullough, P.A., Kelly, R.J., Ruocco, G., Lerma, E., Tumlin, J., Wheelan, K.R., Katz, N., Lepor, N.E., Vijay, K., Carter, H.,
Singh, B., McCullough, S.P., Bhambi, B.K., Palazzuoli, A., De Ferrari, G.M., Milligan, G.P., Safder, T., Tecson, K.M., Wang,
D.D., McKinnon, J.E., O'Neill, W.W., Zervos, M., & Risch, H.A. (2021). Pathophysiological basis and rationale for early
outpatient treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med, 134(1):16-22.
https://doi.org/10.1016/j.amjmed.2020.07.003
Menni, C., Klaser, K., May, A., Polidori, L., Nguzen, L.H., Drew, D.A., Merino, J., Hu, C., Selvachandran, S., Antonelli, M.,
Murray, B., Canas, L.S., Molteni, E., Graham, M.S., Modat, M., Joshi, A.D., Mangino, M., Hammers, A., Goodman, A.L.,
Chan, A.T., Wolf, J., Steves, C.J., Valdes, A.M., Ourselin, S., & Spector, T.D. (2021). Vaccine side-effects and SARS-CoV-2
infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet
Infect Dis, 21(7): 939-949. https://doi.org/10.1016/S1473-3099(21)00224-3
Mereckiene, J. (2018). Seasonal influenza vaccination and antiviral use in EU/EEA Member States. European Centre for Disease
Prevention and Control. https://doi.org/10.2900/721517 or https://www.ecdc.europa.eu/en/publications-data/seasonal-
influenza-vaccination-antiviral-use-eu-eea-member-states
Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E.J., Nadir, E., Olsha-Castell, S., Arad, D., Hasin, T., Levi, N., Asleh, R.,
Amir, O., Meir, K., Cohen, D., Dichtiar, R., Novick, D., Hershkovitz, Y., Dagan, R., Leitersdorf, I., Ben-Ami, R., Miskin, I.,
Saliba, W., Muhsen, K., Levi, Y., Green, M.S., Keinan-Boker, L., & Alroy-Preis, S. (2021). Myocarditis after BNT162b2
mRNA Vaccine against COVID-19 in Israel. N Engl J Med, NEJMoa2109730. https://doi.org/10.1056/NEJMoa2109730
MWGFD, (2021). Mediziner und Wissenschaftler fuer Gesundheit, Freiheit und Demokratie e.V (Association of Physicians and
Scientists for Health, Freedom and Democracy). https://www.mwgfd.de/ (accessed: Dec. 2021)
Miller, M.B., & Bassler, B.L. (2001). Quorum sensing in bacteria. Annu Rev Microbiol, 55: 165-99.
https://doi.org/10.1146/annurev.micro.55.1.165
Moelling, K. (2017). Viruses, More Friends Than Foes. World Scientific, Singapore. ISBN 978-9-813-14782-9.
https://doi.org/10.1142/9789813147836_0001
Mold, M., Shardlow, E., & Exley, C. (2016). Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically
approved human vaccinations. Scientific Reports, 6, 31578. https://doi.org/10.1038/srep31578
Molina, V., & Shoenfeld, Y. (2005). Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity,
38(3):235-45. https://doi.org/10.1080/08916930500050277
Mullis, K., Faloona, F., Scharf, S., Saiki, R., Horn, G., & Erlich, H. (1986). Specific Enzymatic Amplification of DNA In Vitro:
The Polymerase Chain Reaction. Cold Spring Harbor Symposia on Quantitative Biology, 51, 263273.
https://doi.org/10.1101/SQB.1986.051.01.032
Naito, Y., Takagi, T., Yamamoto, T., & Watanabe, S. (2020). Association between selective IgA deficiency and COVID-19. J Clin
Biochem Nutr, 67(2): 122-125. https://doi.org/10.3164/jcbn.20-102
Nair, M.S., Huang, Y., Fidock, D.A., Towler, M.J., & Weathers, P.J. (2021). Artemisia annua hot-water extracts show potent activity
in vitro against Covid-19 variants including delta. bioRxiv, 2021.09.08.459260. https://doi.org/10.1101/2021.09.08.459260
NatBiotech, (2016). Research not fit to print. Nat Biotechnol, 34(2): 115. https://doi.org/10.1038/nbt.3488. PMID: 26849496
Negro, F. (2020). Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? Swiss Med Wkly, 150: w20249.
https://doi.org/10.4414/smw.2020.20249
Nelde, A., Bilich, T., Heitmann, J.S., Maringer, Y., Salih, H.R., Roerden, M., Lübke, M., Bauer, J., Rieth, J., Wacker, M., Peter, A.,
Hörber, S., Traenkle, B., Kaiser, P.D., Rothbauer, U., Becker, M., Junker, D., Krause, G., Strengert, M., Schneiderhan-Marra,
N., Templin, M.F., Joos, T.O., Kowalewski, D.J., Stos-Zweifel, V., Fehr, M., Rabsteyn, A., Mirakaj, V., Karbach, J., Jäger, E.,
Graf, M., Gruber, L.C., Rachfalski, D., Preuss, B., Hagelstein, I., Märklin, M., Bakchoul, T., Gouttefangeas, C., Kohlbacher,
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 203
O., Klein, R., Stevanović, S., Rammensee, H.G., & Walz, J.S. (2021). SARS-CoV-2-derived peptides define heterologous and
COVID-19-induced T cell recognition. Nat Immunol, 22(1):74-85. https://doi.org/10.1038/s41590-020-00808-x
Ng, W.H., Liu, X., & Mahalingam, S. (2020). Development of vaccines for SARS-CoV-2. F1000 Faculty Rev-991.
https://doi.org/10.12688/f1000research.25998.1
Nicolas, E.S. (2021). Advice on AstraZeneca varies across EU, amid blood clot fears. EuObserver.
https://euobserver.com/coronavirus/151485 (accessed: Feb. 2021)
Niesen, M.J.M., Anand, P., Silvert, E., Suratekar, R., Pawlowski, C., Ghosh, P., Lenehan, P., Hughes, T., Zemmour, D., O’Horo,
J.C., Yao, J.D., Pritt, B.S., Norgan, A., Hurt, R.T., Badley, A.D., Venkatakrishnan, A.J., & Soundararajan, V. (2021).
COVID-19 vaccines dampen genomic diversity of SARS-CoV-2: Unvaccinated patients exhibit more antigenic mutational
variance. medRxiv, 2021.07.01.21259833. https://doi.org/10.1101/2021.07.01.21259833
Oller, J. W., & Shaw, C.A. (2019). From superficial damage to invasion of the nucleosome: Ranking of morbidities by the
biosemiotic depth hypothesis. International Journal of Sciences, 8(06), 5173. https://doi.org/10.18483/ijSci.2069
Olliaro, P., Torreele, E., & Vaillant, M. (2021). COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room.
Lancet Microbe, 2(7): e279-e280. https://doi.org/10.1016/S2666-5247(21)00069-0
Olszak, T., An, D., Zeissig, S., Vera, M.P., Richter, J., Franke, A., Glickman, J.N., Siebert, R., Baron, R.M., Kasper, D.L., &
Blumberg, R.S. (2012). Microbial exposure during early life has persistent effects on natural killer T cell function. Science,
336(6080), 489493. https://doi.org/10.1126/science.1219328
Ou, J., Zhou, Z., Dai, R., Zhang, J., Zhao, S., Wu, X., Lan, W., Ren, Y., Cui, L., Lan, Q., Lu, L., Seto, D., Chodosh, J., Wu, J.,
Zhang, G., & Zhang, Q. (2021). V367F Mutation in SARS-CoV-2 Spike RBD emerging during the early transmission phase
enhances viral infectivity through increased human ACE2 receptor binding affinity. Journal of Virology, 95(16), e00617-21.
https://doi.org/10.1128/JVI.00617-21
Pachetti, M., Marini, B., Benedetti, F., Giudici, F., Mauro, E., Storici, P., Masciovecchio, C., Angeletti, S., Ciccozzi, M., Gallo, R.
C., Zella, D., & Ippodrino, R. (2020). Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA
polymerase variant. Journal of Translational Medicine, 18(1), 179. https://doi.org/10.1186/s12967-020-02344-6
Palmieri, V., Perini, G., De Spirito, M., & Papi, M. (2019). Graphene oxide touches blood: in vivo interactions of bio-coronated
2D materials. Nanoscale Horiz, 4(2):273-290. https://doi.org/10.1039/c8nh00318a
Petrik, M. S., Wong, M. C., Tabata, R. C., Garry, R. F., & Shaw, C. A. (2007). Aluminum adjuvant linked to Gulf War Illness
induces motor neuron death in mice. NeuroMolecular Medicine, 9(1), 83100. https://doi.org/10.1385/NMM:9:1:83
PGEI, (2021). Circulating vaccine-derived poliovirus. Polio Global Eradication Initiative, WHO.
https://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/ (accessed: April
2021)
Pujol, A., Gomez, L.-A., Gallegos, C., Nicolau, J., Sanchis, P., Gonzalez-Freire, M., Lopez-Gonzalez, A. A., Dotres, K., &
Masmiquel, L. (2021). Thyroid as a target of adjuvant autoimmunity/inflammatory syndrome due to mRNA-based SARS-
CoV2 vaccination: From Graves’ disease to silent thyroiditis. Journal of Endocrinological Investigation.
https://doi.org/10.1007/s40618-021-01707-0
Rambaut, A., Loman, N., Pybus, O., Barclay, W., Barrett, J., Carabelli, A., Connor, T., Peacock, T., Robertson, D.L., Volz, E.,
COVID-19 Genomics Consortium UK (2020). Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in
the UK defined by a novel set of spike mutations. https://virological.org/t/preliminary-genomic-characterisation-of-an-
emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563 (accessed: Feb. 2021)
Raveendran, A.V., Jayadevan, R., & Sashidharan, S. (2021). Long COVID: An overview. Diabetes & Metabolic Syndrome, 15(3), 869
875. https://doi.org/10.1016/j.dsx.2021.04.007
Reiss, K., & Bhakdi, S. (2020). Corona False Alarm? Facts and Figures, 1st ed. Chelsea Green Publishing. ISBN: 978-1645020578
Rose, J., & McCullough, P.A. (2021) A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting
System (VAERS) in Association with COVID-19 Injectable Biological Products. Curr Probl Cardiol, 101011 ahead of print.
https://doi.org/10.1016/j.cpcardiol.2021.101011
Rosenthal, S., & Cummings, C.L. (2021). Influence of rapid COVID-19 vaccine development on vaccine hesitancy. Vaccine,
S0264-410X(21)01448-1. https://doi.org/10.1016/j.vaccine.2021.11.014
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 204
Salah, H.M., & Mehta, J.L. (2021). COVID-19 vaccine and myocarditis. Am J Cardiol, S0002-9149(21)00639-1.
https://doi.org/10.1016/j.amjcard.2021.07.009
Salle, V. (2021). Coronavirus-induced autoimmunity. Clin Immunol, 226:108694. https://doi.org/10.1016/j.clim.2021.108694
Sander, V.A., Corigliano, M.G., & Clemente, M. (2019). Promising plant-derived adjuvants in the development of coccidial
vaccines. Front Vet Sci, 6:20. https://doi.org/10.3389/fvets.2019.00020
Shoenfeld, Y., & Aron-Maor, A. (2000). Vaccination and autoimmunity-'vaccinosis': a dangerous liaison? J Autoimmun, 14(1):1-
https://doi.org/10. doi: 10.1006/jaut.1999.0346
Schuchat, A. (2021). Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine. Center of Disiease Control &
Prevenetion. https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html (accessed: Feb. 2021)
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic,
G., Muschiol, S., Wullimann, D.J., Kammann, T., Emgård, J., Parrot, T., Folkesson, E., Karolinska COVID-19 Study
Group, Rooyackers, O., Eriksson, L.I., Henter, J.I., Sönnerborg, A., Allander, T., Albert, J., Nielsen, M., Klingström, J.,
Gredmark-Russ, S., Björkström, N.K., Sandberg, J.K., Price, D.A., Ljunggren, H.G., Aleman, S., & Buggert, M. (2020).
Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell, 183(1):158-168.e14.
https://doi.org/10.1016/j.cell.2020.08.017
Seneff, S., Nigh, G. (2021). Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines
against COVID-19. International Journal of Vaccine Theory, Practice, and Research, 2(1): 38-79. Retrieved from
https://ijvtpr.com/index.php/IJVTPR/article/view/23
Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K.J.A., Hemmings, O., O’Bryne, A., Kouphou, N., Pickering, S., Galao, R.P.,
Betancor, G., Wilson, H.D., Signell, A.W., Winstone, H., Kerridge, C., Temperton, N., Snell, L., Bisnauthsing, K., Moore,
A., Green, A., Martinez, L., Stokes, B., Honey, J., Izquierdo-Barras, A., Arbane, G., Pate, A., O’Connell, L., O’Hara, G.,
MacMahon, E., Douthwaite, S., Nebbia, G., Batra, R., Martinez-Nunez, R., Edgeworth, J.D., Neil, S.J.D., Malim, M.H., &
Doores, K.J. (2020). Longitudinal evaluation and decline of antibody responses in 1 SARS-CoV-2 infection. medRxiv,
2020.07.09.20148429. https://doi.org/10.1101/2020.07.09.20148429
Shao, S.C., Wang, C.H., Chang, K.C., Hung, M.J., Chen, H.Y., & Liao, S.C. (2021). Guillain-Barré Syndrome Associated with
COVID-19 Vaccination. Emerg Infect Dis, 27(12): 3175-3178. https://doi.org/10.3201/eid2712.211634
Shaw, C.A., Li, D., & Tomljenovic, L. (2014). Are there negative CNS impacts of aluminum adjuvants used in vaccines and
immunotherapy? Immunotherapy, 6(10), 10551071. https://doi.org/10.2217/imt.14.81
Shaw, C. A., Seneff, S., Kette, S. D., Tomljenovic, L., Oller, J. W., & Davidson, R. M. (2014). Aluminum-induced entropy in
biological systems: Implications for neurological disease. Journal of Toxicology, 491316. https://doi.org/10.1155/2014/491316
Shi, Z., & Puyo, C.A. (2020). Acetylcysteine to Combat COVID-19: An evidence review. Ther Clin Risk Manag, 16: 1047-1055.
https://doi.org/10.2147/TCRM.S273700
Shimoyama, S., Kanisawa, Y., Ono, K., Souri, M., & Ichinose, A. (2021). First and fatal case of autoimmune acquired factor
XIII/13 deficiency after COVID-19/SARS-CoV-2 vaccination. Am J Hematol, 13. https://doi.org/10.1002/ajh.26426
Singh, J.A., & Upshur, R.E.G. (2020). The granting of emergency use designation to COVID-19 candidate vaccines: implications
for COVID-19 vaccine trials. Lancet Infect Dis, 8: S1473-3099(20)30923-3. https://doi.org/10.1016/S1473-3099(20)30923-3
South, A.M., Diz, D., & Chappell, M.C. (2020). COVID-19, ACE2, and the cardiovascular consequences. American Journal of
Physiology-Heart and Circulatory Physiology, 318(5), H1084H1090. https://doi.org/10.1152/ajpheart.00217.2020
Stecklow, S., & Macaskill, A. (2021). The ex-Pfizer scientist who became an anti-vax hero. Reuters Special Report.
https://www.reuters.com/investigates/special-report/health-coronavirus-vaccines-skeptic/ (accessed: Dec. 2021)
Sumi, T., Nagahisa, Y., Matsuura, K., Sekikawa, M., Yamada, Y., Nakata, H., & Chiba, H. (2021). Lung squamous cell carcinoma
with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer-BioNTech). Thorac Cancer, 12: 3072-3075.
https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.14179
SWPRS, (2021). On the Treatment of COVID-19. Swiss Policy Research Report. https://swprs.org/on-the-treatment-of-
COVID-19/ (accessed: Aug. 2021)
Tablizo, F.A., Kim, K.M., Lapid, C.M., Castro, M.J.R., Yangzon, M.S.L., Maralit, B.A., Ayes, M.E.C., Cutiongco-de la Paz, E.M.,
De Guzman, A.R., Yap, J.M.C., Llames, J.S., Araiza, S.M.M., Punayan, K.P., Asin, I.C.A., Tambaoan, C.F.B., Chong, A.L.U.,
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 205
Padilla, K.S.A.R., Cruz, R.P.S., Morado, E.K.D., Dizon, J.G.A., Hao, R.N.M., Zamora, A.A., Pacial, D.R., Magalang, J.A.R.,
Alejandria, M., Carlos, C., Ong-Lim, A., Salvaña, E.M., Wong, J.Q., Montoya, J.C., Singh-Vergeire, M.R., & Saloma, C.P.
(2021). Genome sequencing and analysis of an emergent SARS-CoV-2 variant characterized by multiple spike protein
mutations detected from the Central Visayas Region of the Philippines. medRxiv, 2021.
https://doi.org/10.1101/2021.03.03.21252812
Takano, T., Yamada, S., Doki, T., & Hohdatsu, T. (2019). Pathogenesis of oral type I feline infectious peritonitis virus (FIPV)
infection: Antibody-dependent enhancement infection of cats with type I FIPV via the oral route. J Vet Med Sci, 81(6): 911-
915. https://doi.org/10.1292/jvms.18-0702
TSC, (2021). Nanotechnological investigations on Covid-19 vaccines. White paper on “vaccines’” compositions. The Scientists’
Club. (accessed: Aug. 2021) https://secureservercdn.net/166.62.104.68/19t.39f.myftpupload.com/wp-
content/uploads/2021/09/210819-SCIENTISTS-CLUB-ANALYSIS.pdf
Tomljenovic, L., & Shaw, C.A. (2011). Aluminum vaccine adjuvants: Are they safe? Current Medicinal Chemistry, 18(17): 26302637.
https://doi.org/10.2174/092986711795933740
Toussirot, É., & Bereau, M. (2015). Vaccination and Induction of Autoimmune Diseases. Inflamm Allergy Drug Targets.
2015;14(2):94-8. https://doi.org/10.2174/1871528114666160105113046
Tsumiyama, K., Miyazaki, Y., & Shiozawa, S. (2009). Self-organized criticality theory of autoimmunity. PLoS One, 4(12): e8382.
https://doi.org/10.1371/journal.pone.0008382
Turner, J.S., Kim, W., Kalaidina, E., Goss, C.W., Rauseo, A.M., Schmitz, A.J., Hansen, L., Haile, A., Klebert, M.K., Pusic, I.,
O'Halloran, J.A., Presti, R.M., & Ellebedy, A.H. (2021). SARS-CoV-2 infection induces long-lived bone marrow plasma cells
in humans. Nature, 595: 421-525. https://doi.org/10.1038/s41586-021-03647-4
Ura, T., Okuda, K., & Shimada, M. (2014). Development in viral vector based vaccines. Vaccines, 2(3): 624641;
https://doi.org/10.3390/vaccines2030624
Uriu, K., Kimura, I., Shirakawa, K., Takaori-Kondo, A., Nakada, T.A., Kaneda, A., The Genotype to Phenotype Japan (G2P-
Japan) Consortium, Nakagawa, S., & Sato, K. (2021). Ineffective neutralization of the SARS-CoV-2 Mu variant by
convalescent and vaccine sera. bioRxiv, 2021.09.06.459005. https://doi.org/10.1101/2021.09.06.459005
VAERS, (2021). Searching the VEARS database. Vaccine Adverse Event Reporting System.
https://medalerts.org/vaersdb/index.php (accessed: Feb. 2021); https://openvaers.com/COVID-data/mortality (accessed:
Jan. 2022)
Van Den Bossche, G. (2021). Why should current Covid-19 vaccines not be used for mass vaccination during a pandemic?
Vaccines Summit Ohio 2021 (SOHI021). https://www.geertvandenbossche.org/ (accessed: March 2021)
Villarreal L.P., (2005) Viruses and the Evolution of Life. American Society for Microbiology Press, Washington (DC); ISBN 1-
55581-309-7
Villarreal, L.P., Witzany, G. (2013) Rethinking quasispecies theory: From fittest type to cooperative consortia. World J Biol Chem,
4(4): 79-90. https://doi.org/10.4331/wjbc.v4.i4.79
Villarreal, L.P. (2015) Virolution Can Help Us Understand the Origin of Life. In: Kolb V (ed). Astrobiology An Evolutionary
Approach. CRC Press, Boca Raton (FL); ISBN 13-978-1-4665-8462-4
Villarreal, L.P., Witzany, G. (2021) Social networking of quasi-species consortia drive virolution via persistence. AIMS Microbiology,
7(2): 138-162. https://doi.org/10.3934/microbiol.2021010
Vojdani, A., Vojdani, E., & Kharrazian, D. (2021). Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with
tissue antigens: implications for autoimmune diseases. Front Immunol, 11:617089.
https://doi.org/10.3389/fimmu.2020.617089
Wadman, M. (2021). Israel’s grim warning: Delta can overwhelm shots. Science, 373(6557): 838-839.
https://doi.org/10.1126/science.acx8926
Wall, E.C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P., Hatipoglu, E., Ngai, Y., Hussain, S.,
Nicod, J., Goldstone, R., Ambrose, K., Hindmarsh, S., Beale, R., Riddell, A., Gamblin, S., Howell, M., Kassiotis, G., Libri,
V., Williams, B., Swanton, C., Gandhi, S., & Bauer, D.L. (2021). Neutralising antibody activity against SARS-CoV-2 VOCs
B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet, 19;397(10292): 2331-2333. https://doi.org/10.1016/S0140-
6736(21)01290-3
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 206
Wallukat, G., Hohberger, B., Wenzel, K., Fürst, J., Schulze-Rothe, S., Wallukat, A., Hönicke, A.S., & Müller, J. (2021). Functional
autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl
Autoimmun, 4: 100100. https://doi.org/10.1016/j.jtauto.2021.100100
Wang, J., Lu, L., Song, H., Yang, Y., & Ma, Y. (2010). [Effect of polyethylene glycol as adjuvant on hepatitis B virus DNA vaccine
in vitro]. Wei Sheng Wu Xue Bao = Acta Microbiologica Sinica, 50(7), 949954. https://pubmed.ncbi.nlm.nih.gov/20815244/
Waters, C.M., & Bassler, B.L. (2005). Quorum sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev Bio, 21: 319-46.
https://doi.org/10.1146/annurev.cellbio.21.012704.131001
Watson, J., Whiting, P.F., & Brush, J.E. (2020). Interpreting a covid-19 test result. BMJ, 369: m1808.
https://doi.org/10.1136/bmj.m1808
White, D.O., & Fenner, F.J. (1994) Medical Virology, 4th ed. Academic Press, San Diego (CA). ISBN 0-12-746642-8
WHO, (2021). COVID-19 Vaccine AstraZeneca solution for injection.
https://extranet.who.int/pqweb/sites/default/files/documents/WHO_PL_azd1222.pdf (accessed: Feb. 2021)
Wilson, A. (2021). Dr. Ryan Cole Shares 20-fold Increase of Cancers & Autoimmune Diseases in Vaccinated Population. The True
Defender! https://thetruedefender.com/dr-ryan-cole-shares-20x-increase-of-cancers-autoimmune-diseases-in-vaccinated-
population/ or alternatively: https://vaccinesafety.info/2021/08/26/dr-ryan-cole-stopthemandate/ (accessed: Sep. 2021)
Win-Shwe, T.T., & Fujimaki, H. (2011). Nanoparticles and neurotoxicity. Int J Mol Sci, 12(9): 6267-6280;
https://doi.org/10.3390/ijms12096267
Wise, J. (2021). Covid-19: The E484K mutation and the risks it poses. BMJ, 372: n359. https://doi.org/10.1136/bmj.n359
Witzany, G. (2006). Natural Genome-Editing Competences of Viruses. Acta Biotheorethica, 54: 235-253.
https://doi.org/10.1007/s10441-007-9000-7
Wodarg, W.(2021). Viren sind nicht das Problem - bleiben Sie besonnen! (Viruses are not the problem - stay calm!).
https://www.wodarg.com/about/ (accessed: Dec. 2021)
Wolff, G. (2020). Influenza vaccination and respiratory virus interference among Department of Defense personnel during the
20172018 influenza season. Vaccine, 38: 350354. https://doi.org/10.1016/j.vaccine.2019.10.005
Wood, D., Pereyra, M., Halfon, N., Hamlin, J., & Grabowsky, M. (1995). Vaccination levels in Los Angeles public health centers:
the contribution of missed opportunities to vaccinate and other factors. Am J Public Health, 85(6): 850-853.
https://doi.org/10.2105/ajph.85.6.850
Wraith, D.C., Goldman, M., & Lambert, P.H. (2003). Vaccination and autoimmune disease: what is the evidence? Lancet,
15;362(9396):1659-1666. https://doi.org/10.1016/S0140-6736(03)14802-7
Xu, L., Xiang, J., Liu, Y., Xu, J., Luo, Y., Feng, L., Liu, Z., & Peng, R. (2016). Functionalized graphene oxide serves as a novel
vaccine nano-adjuvant for robust stimulation of cellular immunity. Nanoscale, 14;8(6):3785-95.
https://doi.org/10.1039/c5nr09208f
Xu, L., Ma, Z., Li, Y., Pang, Z., & Xiao, S. (2021). Antibody dependent enhancement: Unavoidable problems in vaccine
development. Adv Immunol, 151:99-133. https://doi.org/10.1016/bs.ai.2021.08.003
Xu, N., Gu, Q., Du, J., Ge, H., Long, S., Sun, W., Fan, J., & Peng, X. (2021). Photodynamic inheritance from methylene blue to
carbon dots against reduction, aggregation, and DNA interference. Science China-Materials, 64(9), 23252336.
https://doi.org/10.1007/s40843-020-1623-4
Yan, B., Chakravorty, S., Mirabelli, C., Wang, L., Trujillo-Ochoa, J.L., Chauss, D., Kumar, D., Lionakis, M.S., Olson, M.R.,
Wobus, C.E., Afzali, B., & Kazemian, M. (2021). Host-virus chimeric events in SARS-CoV2 infected cells are infrequent and
artifactual. BioRxiv, [preprint]: 2021.02.17.431704. https://doi.org/10.1101/2021.02.17.431704
Zhang, L.Z., Jackson, C.B., Mou, H.H., Ojha, A., Rangarajan, E.S., Izard, T., Farzan, M., & Choe, H.Y. (2020a). The D614G
mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. Scripps Research preprint.
https://www.scripps.edu/news-and-events/press-room/2020/20200611-choe-farzan-sars-cov-2-spike-protein.html
(accessed: June 2020).
Zhang, L., Richards, A., Khalil, A., Wogram, E., Ma, H., Young, R.A., & Jaenisch, R. (2020b). SARS-CoV-2 RNA reverse-
transcribed and integrated into the human genome. bioRxiv, [preprint]: 2020.12.12.422516.
https://doi.org/10.1101/2020.12.12.422516
International Journal of Vaccine Theory, Practice, and Research 2(1), January 18, 2022 Page | 207
Zhang, S., Liu, Y., Wang, X., Yang, L., Li, H., Wang, Y., Liu, M., Zhao, X., Xie, Y., Yang, Y., Zhang, S., Fan, Z., Dong, J., Yuan,
Z., Ding, Z., Zhang, Y., & Hu, L. (2020c). SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J
Hematol Oncol, 13(1): 120. https://doi.org/10.1186/s13045-020-00954-7
Zhang, H., & Xia, X. (2021). RNA cancer vaccines: Developing mRNA nanovaccine with self-adjuvant property for cancer
immunotherapy. Human Vaccines & Immunotherapeutics, 17(9), 29952998. https://doi.org/10.1080/21645515.2021.1921524
Zhang, L., Richards, A., Barrasa, M.I., Hughes, S.H., Young, R.A., Jaenisch, R. (2021). Reverse-transcribed SARS-CoV-2 RNA
can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. PNAS, 118 (21),
e2105968118. https://doi.org/10.1073/pnas.2105968118
Legal Disclaimer
The information on the website and in the
IJVTPR
is not intended as a diagnosis, recommended treatment, prevention, or cure
for any human condition or medical procedure that may be referred to in any way. Users and readers who may be parents,
guardians, caregivers, clinicians, or relatives of persons impacted by any of the morbid conditions, procedures, or protocols that
may be referred to, must use their own judgment concerning specific applications. The contributing authors, editors, and persons
associated in any capacity with the website and/or with the journal disclaim any liability or responsibility to any person or entity
for any harm, financial loss, physical injury, or other penalty that may stem from any use or application in any context of
information, conclusions, research findings, opinions, errors, or any statements found on the website or in the
IJVTPR
. The
material presented is freely offered to all users who may take an interest in examining it, but how they may choose to apply any
part of it, is the sole responsibility of the viewer/user. If material is quoted or reprinted, users are asked to give credit to the
source/author and to conform to the non-commercial, no derivatives, requirements of the Creative Commons
License 4.0 NC ND.
... For example, Pujol et al. (2021) report on three cases of thyroiditis which they diagnose as adjuvant induced acute inflammation (ASIA) caused "by the mRNAbased SARS-CoV-2 vaccination" (in their abstract). (Sangaletti, et al. (2022) Recently, however, there have been reports (Broudy & Kyrie, 2021;Wilson, 2021) that some of the denied contents (see our Figure 2 of the statement by the US CDC) are actually included in the COVID-19 vaccines: La Quinta Columna reported poisonous graphene oxide (GO) nanoparticles in COVID-19 vaccines (Campra, 2021), and Robert O. Young, MD, PhD, reported a vade mecum of evidence of toxic nanometallic particles, graphene oxide structures, and parasites in the COVID-19 vaccines (Young, 2021). Moreover, the KoVeDocs also found foreign materials and, as the vaccines were warmed to room temperature, moving and living micro-organisms and parasites could be detected in the Pfizer and Modern mRNA COVID-19 vaccines (Jeon, 2022). ...
Article
Full-text available
The Korea Veritas Doctors (KoVeDocs) for COVID-19 previously found certain foreign materials and moving parasite-like entities in the Pfizer and Moderna mRNA COVID-19 vaccines as those vaccines were warmed to near room temperature (Jeon, 2022). Here we report on similar foreign materials found in samples of centrifuged blood from 8 COVID-19 vaccine recipients as contrasted with 2 individuals who did not receive any COVID-19 vaccine and who had none of the foreign materials in their blood plasma. The preponderance of evidence suggests that the foreign materials found in the COVID-19 vaccine recipients in the study reported here were injected into their bodies when they received one or more doses of the COVID-19 vaccines. Blood samples were prepared and observed under a stereomicroscope after being centrifuged at 2,200 rpm for 30 minutes. From the 8 COVID-19 vaccine recipients: 6 plasma samples contained a multilayered disc of unidentified composition; 3 samples contained beaded coil-like materials; 1 plasma sample contained a fibrous bundle of similar appearing beaded foreign material; and a different group of 3 samples had crystal-like formations of foreign material. The various shapes and sizes of foreign materials in the centrifuged plasmas of COVID-19 vaccinated individuals closely resembled the shapes and sizes of foreign materials previously observed directly in the vaccines themselves. These findings are the basis for our recommendation that (a) a collaborative worldwide evaluation of COVID-19 vaccine contents, and of the blood and plasma samples of COVID-19 vaccinated individuals, be undertaken immediately with all due diligence; (b) that there should be an immediate cessation of COVID-19 vaccinations worldwide and the abandonment of any COVID-19 “Vaccine Pass Policy” and any other form of mandate for COVID-19 vaccinations; and, (c) that emergency collaborative studies of detoxification protocols for COVID-19 vaccine sequelae be undertaken.
Preprint
Full-text available
The COVID-19 pandemic and the recently-emerged highly transmissible SARS-CoV-2 Omicron variants have increased the demands for novel immunising and therapeutic approaches to protect the lives of patients with significant co-morbidities. Following a worldwide campaign of mass vaccination, there is still a significant demand to quell the harmful effects of the novel SARS-CoV-2 variants on people with serious co-morbidities, and there is still a dilemma of how we could prevent potentially catastrophic effects of future pandemics upon the human race. And the concerns intersect at a specific point; a gained evolutionary ability of several viruses over the previous centuries to go undetected during the first stages of infection by means of capping the 5' end of their genetic material, reducing the synthetic rate of Type I and Type III Interferons, temporarily inhibiting the apoptotic pathways of infected cells to facilitate a rapid viral replication, and inhibiting antigenic presentation. Type I and III Interferon-based viral immune evasion may be primarily associated with a delayed clearance of the viral load. Past clinical data also suggests that the SARS-CoV-2 spike glycoprotein is capable of inhibiting the V(D)J antibody gene rearrangement in developing B-lymphocytes, as well as diverse important cellular processes of DNA repair by downregulating the BRCA1 and 53BP1 genes. Furthermore, most traditional methods of vaccination do not particularly boost mucosal immunity and as a result, there is a visible gap that viruses can easily fill in, which implicates a reduced stimulation of a mucosal plasma cell production. Serum plasma antibodies do not cross the nasal epithelium and hence, offer little protection against mucosal inflammation, unlike the antibodies produced by mucosal plasma cells. We acknowledge the existence of a significant challenge to stimulate mucosal immune responses due to the high complexity of its structure-function axis. Nevertheless, over the past half century, numerous scientists developed ways of immunisation and early treatment worldwide that generally showed outstanding levels of success and insignificant risks of adverse events. An important example implicates the administration of human interferons I and III into the nasal mucosa to simulate local infection and train the innate immune system to robustly become activated and transmit essential signals before viruses silence it. Recently, it was discovered that specific plants secrete proteins that also stimulate the production of Type I Interferons. It might be that focusing on directly offering the immune system the information about the genetics and protein structure of the pathogen, rather than training its first-line mechanisms to develop faster, excessively increases its specificity, making it reach a level that brings the virus the opportunity to evolve and escape previously-developed host immune mechanisms. Naturally-selected polymorphic viruses had generated long-term evolutionary responses to deeply tackle the ability of the complex human immune system to neutralise viruses during the first stages of cellular infection. It is until the scientific community realises this that we will probably continue to face serious epidemics and pandemics of respiratory diseases over the coming several decades.
Preprint
Full-text available
The COVID-19 pandemic and the recently-emerged highly transmissible SARS-CoV-2 Omicron variants have increased the demands for novel immunising and therapeutic approaches to protect the lives of patients with significant co-morbidities. Following a worldwide campaign of mass vaccination, there is still a significant demand to quell the harmful effects of the novel SARS-CoV-2 variants on people with serious co-morbidities, and there is still a dilemma of how we could prevent potentially catastrophic effects of future pandemics upon the human race. And the concerns intersect at a specific point; a gained evolutionary ability of several viruses over the previous centuries to go undetected during the first stages of infection by means of capping the 5' end of their genetic material, reducing the synthetic rate of Type I and Type III Interferons, temporarily inhibiting the apoptotic pathways of infected cells to facilitate a rapid viral replication, and inhibiting antigenic presentation. Type I and III Interferon-based viral immune evasion may be primarily associated with a delayed clearance of the viral load. Past clinical data also suggests that the SARS-CoV-2 spike glycoprotein is capable of inhibiting the V(D)J antibody gene rearrangement in developing B-lymphocytes, as well as diverse important cellular processes of DNA repair by downregulating the BRCA1 and 53BP1 genes. Furthermore, most traditional methods of vaccination do not particularly boost mucosal immunity and as a result, there is a visible gap that viruses can easily fill in, which implicates a reduced stimulation of a mucosal plasma cell production. Serum plasma antibodies do not cross the nasal epithelium and hence, offer little protection against mucosal inflammation, unlike the antibodies produced by mucosal plasma cells. We acknowledge the existence of a significant challenge to stimulate mucosal immune responses due to the high complexity of its structure-function axis. Nevertheless, over the past half century, numerous scientists developed ways of immunisation and early treatment worldwide that generally showed outstanding levels of success and insignificant risks of adverse events. An important example implicates the administration of human interferons I and III into the nasal mucosa to simulate local infection and train the innate immune system to robustly become activated and transmit essential signals before viruses silence it. Recently, it was discovered that specific plants secrete proteins that also stimulate the production of Type I Interferons. It might be that focusing on directly offering the immune system the information about the genetics and protein structure of the pathogen, rather than training its first-line mechanisms to develop faster, excessively increases its specificity, making it reach a level that brings the virus the opportunity to evolve and escape previously-developed host immune mechanisms. Naturally-selected polymorphic viruses had generated long-term evolutionary responses to deeply tackle the ability of the complex human immune system to neutralise viruses during the first stages of cellular infection. It is until the scientific community realises this that we will probably continue to face serious epidemics and pandemics of respiratory diseases over the coming several decades.
Article
Full-text available
How and why has it come to pass that children as young as 12 in the UK are being injected with a novel form of mRNA technology that is unlicensed, has no long-term safety data, and remains in clinical trials until May 2023? This article traces the path by which the unthinkable became an alarming reality between October 2020 and September 2021 and also follows developments since then. Working chronologically, the actions and claims of the manufacturers, the regulators, politicians, and in particular the establishment media in promoting “COVID-19 vaccination” for children are examined. The actions taken by policy makers are juxtaposed to scientific evidence available showing that there has never been any rational justification for the mass rollout of “COVID-19 vaccines” to children. The rollout has been predicated on shifting narratives, obfuscations, faux justifications, outright lies, regulatory capture of supposed guardians of the public interest, and mass propaganda. Evidence of actual and potential injuries to children has accumulated from before the beginning of the rollout, in spite of repeated attempts to cover it up, and yet, the under-12s are now also in the crosshairs and children are being targeted for “booster shots.” A clear picture emerges of collusion and corruption at the highest levels in forcing through an agenda that runs contrary to public health, democracy, and freedom. It is becoming clear that the rollout to children has nothing to do with “SARS-CoV-2” and everything to do with ongoing efforts to refashion the international monetary system in the image of central bank digital currencies and biometric IDs. In pursuit of that agenda, the transnational ruling class has revealed that it is willing to maim and kill children knowingly, creating enormous potential for a backlash as the public becomes aware of what is being done.
Article
Full-text available
La proteina ingegnerizzata spike della SARS-COV-2 e la corrispondente malattia infettiva COVID-19 attribuita ad essa tengono in pugno una gran parte dell'umanità. La corsa globale per una strategia di contrasto si è rapidamente trasformata nella ricerca di un vaccino come mezzo preferenziale per contenere il virus. Uno sviluppo insolitamente rapido di diverse classi completamente nuove di terapie sperimentali diffuse come "vaccini", ha sollevato interrogativi sulla sicurezza, in particolare per quanto riguarda l'approvazione dell'uso di emergenza (EUA) che è stata concessa con un'urgenza senza precedenti e priva di qualsiasi esame critico contrario. Attualmente, ricercatori indipendenti, come anche alcuni ex proponenti e addetti ai lavori dell'esperimento globale attualmente in corso e rappresentato come una campagna di "vaccinazione", sottolineano soprattutto la mancanza di studi sulla sicurezza della campagna vaccinale che ha finito invece per strutturarsi su set di dati empirici che verranno ottenuti attraverso decine di milioni, anche centinaia di milioni, di dosi di mRNA e terapie vettoriali del DNA distribuite col nome di "vaccini". Gli studi riguardanti l'efficacia e gli "effetti collaterali" (talvolta fatalità o lesioni iatrogene permanenti) di queste terapie sperimentali sono stati omessi a favore di dati a breve termine presi sul campo su pazienti reali. Questa evidenza solleva inevitabilmente questioni scientifiche ed etiche, in particolare in considerazione del fatto che le persone e gli enti responsabili per la sicurezza pubblica hanno vasti interessi finanziari e di altro tipo che li portano ad accelerare la distribuzione di questi prodotti farmaceutici sperimentali. La mancanza di una discussione aperta sulle terapie sperimentali per il COVID-19 ora applicate su tutte le fasce di età, anche i bambini, che difficilmente sono colpiti dal COVID-19, è preoccupante. Il principio fondamentale del dibattito aperto senza preconcetti o sugli interessi nei risultati è stato e continua ad essere completamente ignorato. Speriamo di impegnare una discussione scientifica al fine di aiutare chi deve decidere, l'opinione pubblica e i media a considerare l'oggetto di ciò che è in gioco in un contesto di ragione piuttosto che di panico.
Article
Full-text available
A hyperimmune state secondary to dysregulation of the immune system during lower pulmonary viral infections, sepsis and in some cases non-infectious disorders, is now considered to be the principle event leading to clinical deterioration and eventual death in these patients. While most studies have attributed the pathological damage to the lung to be primarily due to high levels of cytokines and chemokines along with massive infiltration of principally neutrophils and macrophages, there is compelling evidence that overactivation of glutamate receptors is also playing a significant, if not critical role in this process. Functional glutamate receptors, along with two important glutamate transport systems, have now been described in epithelial and endothelial cells in the pulmonary airways as well as all involved immune cells. Experimental studies using cytokine models have shown considerable protection against pathological damage to pulmonary tissues by reducing the activation of these glutamate receptors.
Article
Full-text available
Operation Warp Speed brought to market in the United States two mRNA vaccines, produced by Pfizer and Moderna. Interim data suggested high efficacy for both of these vaccines, which helped legitimize Emergency Use Authorization (EUA) by the FDA. However, the exceptionally rapid movement of these vaccines through controlled trials and into mass deployment raises multiple safety concerns. In this review we first describe the technology underlying these vaccines in detail. We then review both components of and the intended biological response to these vaccines, including production of the spike protein itself, and their potential relationship to a wide range of both acute and long-term induced pathologies, such as blood disorders, neurodegenerative diseases and autoimmune diseases. Among these potential induced pathologies, we discuss the relevance of prion-protein-related amino acid sequences within the spike protein. We also present a brief review of studies supporting the potential for spike protein "shedding", transmission of the protein from a vaccinated to an unvaccinated person, resulting in symptoms induced in the latter. We finish by addressing a common point of debate, namely, whether or not these vaccines could modify the DNA of those receiving the vaccination. While there are no studies demonstrating definitively that this is happening, we provide a plausible scenario, supported by previously established pathways for transformation and transport of genetic material, whereby injected mRNA could ultimately be incorporated into germ cell DNA for transgenerational transmission. We conclude with our recommendations regarding surveillance that will help to clarify the long-term effects of these experimental drugs and allow us to better assess the true risk/benefit ratio of these novel technologies.
Article
Full-text available
Rationale: Transverse myelitis is an infectious or noninfectious inflammatory spinal cord syndrome. We report a rare case of transverse myelitis following vaccination against COVID-19. Patient concerns: A 70-year-old male presented with progressive sensorimotor dysfunction of the bilateral lower limbs 7 days after receiving the mRNA-1273 vaccine against COVID-19. Spinal magnetic resonance imaging revealed intramedullary lesions with gadolinium enhancement on the Th1/2 and Th5/6 vertebral levels. Cerebrospinal fluid (CSF) testing showed a mildly increased level of total protein and positive oligoclonal bands (OCB). Diagnosis: The patient was diagnosed with acute transverse myelitis. Intervention: The patient received 5 days of intravenous methylprednisolone pulse (1000 mg/day) followed by oral prednisolone (30 mg/day with gradual tapering). Outcomes: The patient fully recovered from muscle weakness of the lower limbs. He was discharged from our hospital and able to independently walk without unsteadiness. Lesson: This is a rare case of transverse myelitis following COVID-19 vaccination. Positive OCB in CSF in the present case highlights the possibility of autoimmune processes, including polyclonal activation of B lymphocytes, following vaccination.
Preprint
Full-text available
Background A rapid increase in cases due to the SARS-CoV-2 Omicron (B.1.1.529) variant in highly vaccinated populations has raised concerns about the effectiveness of current vaccines. Methods We used a test-negative case-control design to estimate vaccine effectiveness (VE) against symptomatic disease caused by the Omicron and Delta variants in England. VE was calculated after primary immunisation with two BNT162b2 or ChAdOx1 doses, and at 2+ weeks following a BNT162b2 booster. Results Between 27 November and 06 December 2021, 581 and 56,439 eligible Omicron and Delta cases respectively were identified. There were 130,867 eligible test-negative controls. There was no effect against Omicron from 15 weeks after two ChAdOx1 doses, while VE after two BNT162b2 doses was 88.0% (95%CI: 65.9 to 95.8%) 2-9 weeks after dose 2, dropping to between 34 and 37% from 15 weeks post dose 2.From two weeks after a BNT162b2 booster, VE increased to 71.4% (95%CI: 41.8 to 86.0%) for ChAdOx1 primary course recipients and 75.5% (95%CI: 56.1 to 86.3%) for BNT162b2 primary course recipients. For cases with Delta, VE was 41.8% (95%CI: 39.4-44.1%) at 25+ weeks after two ChAdOx1 doses, increasing to 93.8% (95%CI: 93.2-94.3%) after a BNT162b2 booster. With a BNT162b2 primary course, VE was 63.5% (95%CI: 61.4 to 65.5%) 25+ weeks after dose 2, increasing to 92.6% (95%CI: 92.0-93.1%) two weeks after the booster. Conclusions Primary immunisation with two BNT162b2 or ChAdOx1 doses provided no or limited protection against symptomatic disease with the Omicron variant. Boosting with BNT162b2 following either primary course significantly increased protection.
Article
Full-text available
Incontrovertible evidence has now made clear that much of what has been perceived publicly about the story of SARS-CoV-2 and the pharmaceutical remedies offered (then mandated) was/is part of a sophisticated international fabrication of unprecedented proportion, depth, and deception. The origins of the virus, the approved testing regime, the flawed predictive models of spread and mortality, associated social-distancing mandates, and so-called vaccines and their claimed efficacy and safety, all point to a coordinated effort to manufacture public fear and hysteria so as to propagate and normalize transhumanist interventions in healthcare and human biology. This article begins with the simple question of how adjuvants in traditional vaccines are theorized to work and proceeds to analyze how the new injectable mRNA platforms deploy nanomaterials as delivery vehicles for genetic interventions with a range of other potential actions inside the human body, both intended and unintended. The authors draw upon the chronological and logical development of adjuvants and their use across disciplines in materials science, genetic engineering, and programming. The authors aim to disentangle the known, unknown, possible and likely contents and objectives of COVID-19 injections, in the context of the surrounding corporate, political, and ideological landscape. They conclude that the social disruptions created by COVID-19 have served as a means of instigating rapid transition to what unelected policymakers have called a Bio-Nano Age.
Article
Full-text available
Since nucleoside-modified mRNA vaccines strongly activate T follicular helper cells, it is important to explore the possible impact of approved SARS-CoV-2 mRNA vaccines on neoplasms affecting this cell type. Herein, we report and discuss unexpected rapid progression of lymphomatous lesions after administration of a BNT162b2 mRNA vaccine booster in a man recently diagnosed with AITL.
Article
Full-text available
Vaccines have been developed at “warp speed” to combat the COVID-19 pandemic caused by the SARS-CoV-2 coronavirus. Although they are considered the best approach for preventing mortality, when assessing the safety of these vaccines, pregnant women have not been included in clinical trials. Thus, vaccine safety for this demographic, as well as for the developing fetus and neonate, remains to be determined. A global effort has been underway to encourage pregnant women to get vaccinated despite the uncertain risk posed to them and their offspring. Given this, post-hoc data collection, potentially for years, will be required to determine the outcomes of COVID-19 and vaccination on the next generation. Most COVID-19 vaccine reactions include injection site erythema, pain, swelling, fatigue, headache, fever and lymphadenopathy, which may be sufficient to affect fetal/neonatal development. In this review, we have explored components of the first-generation viral vector and mRNA COVID-19 vaccines that are believed to contribute to adverse reactions and which may negatively impact fetal and neonatal development. We have followed this with a discussion of the potential for using an ovine model to explore the long-term outcomes of COVID-19 vaccination during the prenatal and neonatal periods.
Article
Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an unprecedented setback for global economy and health. Vaccination is one of the most effective intervention to substantially reduce severe disease and death due to SARS-CoV-2 infection. Vaccination programs are being rolled out globally, but most of these vaccines have been approved without extensive studies on their side effects and efficacy. Recently, new-onset autoimmune phenomena after COVID-19 vaccination have been reported increasingly (e.g., immune thrombotic thrombocytopenia, autoimmune liver diseases, Guillain-Barré syndrome, IgA nephropathy, rheumatoid arthritis and systemic lupus erythematosus, etc.). Molecular mimicry, the production of particular autoantibodies and the role of certain vaccine adjuvants seem to be substantial contributors to autoimmune phenomena. However, whether the association between COVID-19 vaccine and autoimmune manifestations is coincidental or causal remains to be elucidated. Here, we summarize the emerging evidence about autoimmune manifestations occurring in response to certain COVID-19 vaccines. Although information pertaining to the risk of autoimmune disease as a consequence of vaccination is controversial, we merely propose our current understanding of autoimmune manifestations associated with COVID-19 vaccine. In fact, we do not aim to disavow the overwhelming benefits of mass COVID-19 vaccination in preventing COVID-19 morbidity and mortality. These reports could help guide clinical assessment and management of autoimmune manifestations after COVID-19 vaccination.
Preprint
The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) break through infection- or vaccine-induced immunity is not well understood. Here, we analyze 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We find evidence for an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared to the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14-59 days after complete vaccination compared to 60 days and longer. In contrast to vaccine-induced immunity, no increased risk for reinfection with Beta, Gamma or Delta variants relative to Alpha variant was found in individuals with infection-induced immunity.